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KEY POINTS 55 
 Chronic constipation is a common disorder with a reported prevalence 56 
ranging from 3-27% in the general population. Multiple management 57 
strategies, including diagnostic tests, empiric treatments and specific 58 
treatments are known to be used. 59 
 The aim of the present manuscript was to create European guidelines for 60 
the clinical management of constipation, developed by experts in different 61 
fields related to constipation across Europe. 62 
  After a full review of the literature, relevant statements, final 63 
recommendations and management algorithms were produced using a 64 
Delphi consensus process.  65 
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ABSTRACT 66 
INTRODUCTION: Chronic constipation is a common disorder with a reported 67 
prevalence ranging from 3-27% in the general population. Several management 68 
strategies, including diagnostic tests, empiric treatments and specific treatments 69 
have been developed. Our aim was to develop European guidelines for the clinical 70 
management of constipation. 71 
DESIGN: After a thorough review of the literature by experts in relevant fields, 72 
including gastroenterologists, surgeons, general practitioners, radiologists and 73 
experts in gastrointestinal motility testing from various European countries, a Delphi 74 
consensus process was used to produce statements and practical algorithms for the 75 
management of chronic constipation. 76 
KEY RESULTS: Seventy-three final statements were agreed upon after the Delphi 77 
process. The level of evidence for most statements was low or very low. A high level 78 
of evidence was agreed only for anorectal manometry as a comprehensive 79 
evaluation of anorectal function and for treatment with osmotic laxatives, especially 80 
polyethylene glycol, the prokinetic drug prucalopride, secretagogues such as 81 
linaclotide and lubiprostone and PAMORAs for the treatment of opioid-induced 82 
constipation. However, the level of agreement between the authors was good for 83 
most statements (80% or more of the authors). The greatest disagreement was 84 
related to the surgical management of constipation. 85 
CONCLUSIONS & INFERENCES: European guidelines on chronic constipation, with 86 
recommendations and algorithms, were developed by experts. Despite the high level 87 
of agreement between the different experts, the level of scientific evidence for most 88 
recommendations was low, highlighting the need for future research to increase the 89 
evidence and improve treatment outcomes in these patients. 90 
 91 
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INTRODUCTION 95 
Chronic constipation is a common disorder with a reported prevalence ranging from 96 
3-27% in the general population.1, 2 Its prevalence increases with age,3, 4 and 97 
consequently is expected to rise over the next few years,5 in parallel with the 98 
predicted increase in longevity of the European population. Constipation is a 99 
symptom that may have diverse aetiologies, and for this reason, several diagnostic 100 
approaches and treatment options are available, ranging from simple lifestyle 101 
changes and general measures to sophisticated pharmacological treatments and 102 
surgical interventions.6 In an attempt to unify the health care received by the 103 
population across Europe, the European Society of Neurogastroenterology and 104 
Motility (ESNM) decided to develop European guidelines to help physicians to take 105 
the best decisions to improve the quality of health in patients suffering from common 106 
functional and motor disorders. In this document, we present the ESNM guidelines 107 
for chronic constipation, which are intended to be a useful tool for the management 108 
of this condition in the general population in Europe. In order to produce 109 
comprehensive guidelines addressing the different aspects related with constipation, 110 
experts from European countries working in related fields developed relevant 111 
statements after a thorough review of the available literature, and final 112 
recommendations and management algorithms were produced following a Delphi 113 
consensus process.  114 
 115 
  116 
7 
 
METHODS 117 
Participants 118 
A chair (Jordi Serra) and co-chair (Daniel Pohl) were commissioned by the ESNM 119 
Steering Committee to develop the guidelines. A panel of 12 experts from different 120 
European countries, constituted by gastroenterologists, surgeons, general 121 
practitioners, radiologists and experts in gastrointestinal (GI) motility testing, was 122 
invited by the chairs to participate in the development of the guidelines. Each expert 123 
was assigned to develop a specific area of the document (see below), and to 124 
establish a team with one or two co-workers to complete the assigned task. The final 125 
ESNM guidelines working group was composed of 13 experts and 9 co-authors.  126 
 127 
The Delphi consensus 128 
Each expert and co-worker conducted a thorough review of the literature in their 129 
specific field of expertise. The following areas were covered by the different 130 
subgroups: 1. Definition. 2. Pathophysiology: causes and predisposing factors. 3. 131 
Diagnostic approach: clinical approach and basic investigations; functional studies; 132 
radiological studies. 4. Treatment: Lifestyle and general measures; bulking agents 133 
and osmotic laxatives; stimulant laxatives; prokinetics and secretagogues; 134 
biofeedback therapy; alternative treatments; probiotics; and surgical treatment. 135 
Based on the results of the search, several statements with specific 136 
recommendations were produced by each expert and rated according to the level of 137 
evidence. The Grading of Recommendations, Assessment, Development and 138 
Evaluation (GRADE) was used to rate the level of evidence and recommendation. In 139 
parallel, an algorithm for the management of constipation was developed by the 140 
chair. When all the statements had been received from all the authors, a Delphi 141 
consensus process was initiated by sending all the statements and algorithms to all 142 
the experts for anonymous voting, with progressive refinement and re-voting of the 143 
re-formulated statements.  144 
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Finally, each expert wrote the final statements corresponding to the assigned 145 
section, including comments, unmet needs and the literature supporting the evidence 146 
of the recommendations, and three algorithms for the management of constipation 147 
were produced. The level of agreement between authors for each statement is 148 
shown in Figure 1. 149 
 150 
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 161 
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RESULTS 173 
DEFINITION 174 
Statement 1: Constipation is defined as difficult, unsatisfactory or infrequent 175 
defecation. 176 
a. Level of evidence: Not applicable 177 
b. Recommendation: Not applicable 178 
c. Level of agreement: 100% (Figure 1).  179 
This definition is consistent with the definitions of chronic constipation used in recent 180 
guidelines and in the Rome consensus for functional constipation (FC).7, 8 The term  181 
unsatisfactory evacuation has been chosen as a general and comprehensive term 182 
that includes, among others, feeling of incomplete evacuation.  The term difficult 183 
evacuation includes straining, sensation of anorectal obstruction and need for 184 
manual manoeuvres to facilitate evacuation. 185 
 186 
 187 
PATHOPHYSIOLOGY 188 
CAUSES AND PREDISPOSING FACTORS 189 
Statement 2: The prevalence of constipation is higher in women  190 
a. Level of evidence: High 191 
b. Recommendation: Not applicable 192 
c. Level of agreement: 100% 193 
 194 
Current evidence and literature: 195 
The available evidence points towards a clear sex preponderance in women. Most of 196 
the studies in a systematic review9 reported a predominance of females in the 197 
prevalence of constipation. The mean female/male ratio was 1.78 (median 1.58), but 198 
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differed according to the definition of constipation (1.7 for Rome I, 1.8 for Rome II 199 
and 2.3 for self-reporting of constipation). 200 
Female predominance was also shown in a recent epidemiological study in FC 201 
patients based on Rome III Criteria, with a higher prevalence in female (17.4%) 202 
compared to male students (12.5%).10 In univariate logistic regression analysis, FC 203 
was significantly associated with sex (odds ratio [OR] 1.48, 95% confidence interval 204 
[CI] 1.06-2.06). In a different population of 7251 constipated patients and 7103 205 
controls, Talley et al.3 showed an OR of 1.62 (95% CI 1.49-1.76) in females. This 206 
predominance of females has been attributed to hormonal factors, such as a higher 207 
risk of constipation during the luteal phase of the menstrual cycle and the effect of 208 
progesterone, most notably in pregnancy, as well as damage to the pelvic floor 209 
muscles that may occur in women during childbirth or gynaecological surgery. This 210 
effect of additional progesterone on colonic transit could also be confirmed in a 211 
prospective study by Gonenne et al.11 in 49 postmenopausal women.  212 
Additionally, premenopausal women (age 25-49) were shown to have longer transit 213 
times than older women (64.0 vs 59.5 hours; difference 4.6 hours, 95% CI 1.1-8.1 214 
hours)12. This leads to less pronounced gender differences in constipation 215 
prevalence in the older population. 216 
 217 
 218 
Future research/unmet needs: 219 
Investigations on further pathophysiological differences except for the hormonal 220 
situation between men and women should be done.  221 
Statement 3: The prevalence of constipation increases with age 222 
a. Level of evidence: High 223 
b. Recommendation: Not applicable 224 
c. Level of agreement: 100% 225 
 226 
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Current evidence and literature: 227 
It is generally perceived that the prevalence of constipation increases with age. In a 228 
postal health survey in 41 724 Australian women,4 the prevalence of constipation 229 
was 14.1% (CI 13.5–14.7) in young women (18-23 years), 26.6% (CI 25.9–27.4) in 230 
middle-aged women (45-50 years) and 27.7% (CI 26.9–28.5) in older women (70-75 231 
years). In data analyses from the General Practice Research Database (GPRD) in 232 
the United Kingdom, Talley et al.3 showed a higher OR of constipation in patients 233 
>75 years compared to controls (OR 1.96, 95% CI 1.71-2.24).  234 
 235 
Future research/unmet needs: 236 
The effects of ageing on intestinal connective tissue, influence of hormonal status in 237 
relation to gut motility and age-related changes in the microbiome should be 238 
evaluated to analyse functional, intestinal and external structures as underlying 239 
causes of constipation and defecation disorders.  240 
 241 
Statement 4: A positive family history of constipation predisposes the 242 
individual to constipation, including earlier age of onset, longer duration and 243 
higher rate of complications 244 
a. Level of evidence: Low 245 
b. Recommendation: Not applicable 246 
c. Level of agreement: 100 % 247 
 248 
Current evidence and literature: 249 
Genetics and/or epigenetics may play a role in FC. Chan et al.13 analysed the clinical 250 
characteristics of FC in 118 FC patients and 114 patients without FC according to the 251 
Rome II questionnaire. Patients with a positive family history of FC showed younger 252 
age at onset (median 11-20 years vs 21-30 years, p<0.001) and longer duration of 253 
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constipation (20±14 vs 15±13, p=0.016). Additionally, more complications, e.g. 254 
symptomatic haemorrhoids, anal fissure and rectal prolapse (54.2% vs 40.4%, 255 
p=0.034); fewer precipitating factors leading to the onset of constipation (35.6% vs 256 
49.1%, p=0.037) and more frequent use of digital evacuation (27.1% vs 13.2%, 257 
p=0.008) were seen in patients with a positive family history of FC. Another study by 258 
Ostwani et al.14  demonstrated significantly higher rates of constipation in siblings or 259 
parents of children with functional, habitual constipation than in controls (30% vs 7% 260 
and 42% vs 9%, respectively; p=0.001). 261 
 262 
Future research/unmet needs: 263 
Genetic and epigenetic studies are needed. 264 
 265 
Statement 5: Lower social, economic and educational levels are associated 266 
with a higher prevalence of constipation 267 
a. Level of evidence: Low 268 
b. Recommendation: Not applicable 269 
c. Level of agreement: 100 % 270 
 271 
Current evidence and literature: 272 
In general, individuals of lower social, economic and educational levels have a 273 
tendency towards higher constipation rates. Bytzer et al.15 divided the sample of their 274 
questionnaire survey into five socioeconomic classes from 1st (highest) to 5th 275 
(lowest). They showed that the standardised prevalence rate (95% CI) for 276 
constipation symptoms was lowest in the 1st quintile (2.81 in males and 8.53 in 277 
females) compared to the 2nd to 5th quintile (4.03, 6.99, 5.68 and 5.15 in men, and 278 
14.06, 13.35, 13.95 and 14.31 in women). Of interest, according to another study,16 279 
constipation correlated with a low maternal educational level (1.60; 1.08-2.35). 280 
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However, there may be a composite effect of socioeconomic class and a low fibre 281 
intake. In a systematic review including 75 different studies, Allen et al.17 concluded 282 
that there was less consumption of fibre, fruit and vegetables in lower socioeconomic 283 
classes.  284 
 285 
Future research/unmet needs: 286 
Prospective behavioural studies are of interest, however will be unlikely to change 287 
practice. 288 
 289 
Statement 6: After careful exclusion of a defecatory disorder with anorectal 290 
function testing including defecography, at least half of patients with 291 
functional constipation do not show signs of delayed colonic transit 292 
a. Level of evidence: Low 293 
b. Recommendation: Not applicable 294 
c. Level of agreement: 82% 295 
 296 
Current evidence and literature: 297 
Different pathophysiological mechanisms may lead to FC. Constipation can be 298 
classified into three categories: functional defecatory disorders, normal colonic transit 299 
and slow colonic transit.18 In a review of medical records, 1411 patients were 300 
analysed between 1994 and 2011 by a single gastroenterologist. The majority (960, 301 
68%) of patients had normal transit constipation (NTC), 390 (28%) had dyssynergic 302 
defecation (DD) (abnormal balloon expulsion test and/or high anal sphincter pressure 303 
and/or failure of the anorectal angle to open) and 61 (1%) suffered from slow-transit 304 
constipation (STC) (diagnosed by colon transit scintigraphy).19 305 
 306 
Future research/unmet needs: 307 
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There is still a lack of understanding how best to separate individual patient 308 
symptomatology from meaningful pathologic transit. Further research is needed in 309 
this area.   310 
 311 
Statement 7: There is increased prevalence of rectal hyposensitivity in 312 
constipation 313 
a. Level of evidence: Very low 314 
b. Recommendation: Not applicable 315 
c. Level of agreement: 100% 316 
 317 
Current evidence and literature: 318 
Shekar et al.20 demonstrated anorectal hyposensitivity in FC (27%) compared to 319 
constipation-predominant irritable bowel syndrome (IBS-C) patients (4%) using 2.5th 320 
and 97.5th percentiles for pain threshold for healthy volunteers (18 mmHg and 42 321 
mmHg, respectively). Hypersensitivity was seen in 30% IBS-C patients and no FC 322 
patients. 323 
Another study by Gladman et al.21 also showed a higher prevalence of rectal 324 
hyposensitivity in patients with constipation (23%) and incontinence associated with 325 
constipation (27%) compared to patients with faecal incontinence only (10%) and 326 
“others” (patients with anorectal physiologic investigations without constipation or 327 
faecal incontinence, 5%). 328 
 329 
Future research/unmet needs: 330 
Research should be conducted on the mechanisms/pathophysiology of the 331 
development of hyposensitivity (primary, secondary) in constipation. 332 
 333 
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Statement 8: The volume of interstitial cells of Cajal in the sigmoid colon and 334 
the neuronal structures within the colonic circular smooth muscle layer are 335 
decreased in patients with slow-transit constipation 336 
a. Level of evidence: Low 337 
b. Recommendation: Not applicable 338 
c. Level of agreement: 100% 339 
 340 
Current evidence and literature: 341 
The pathophysiology of constipation, in particular STC, is not completely understood. 342 
Focusing on motility, He et al.22 analysed the role of interstitial cells of Cajal (ICC) in 343 
STC patients. They found a significantly decreased volume of ICC in all layers of 344 
sigmoid colonic specimens in STC patients compared to controls. Neuronal 345 
structures within the colonic circular smooth muscle layer were also decreased. 346 
 347 
Future research/unmet needs: 348 
Research should be conducted on the mechanisms/pathophysiology of the 349 
development of hypo-/dysmotility in constipation. Current studies with histological 350 
data come from very select patients with more pronounced symptoms, that may not 351 
be representative of ordinary constipation. A way to move forward would make use of 352 
recent developments such as full thickness resection devices, that allow endoscopic 353 
retrieval of representative specimen23  354 
 355 
Statement 9: Evacuation disorders represent an important underlying cause of 356 
constipation and should be excluded before diagnosing isolated slow-transit 357 
constipation 358 
a. Level of evidence: Moderate 359 
b. Recommendation: Strong 360 
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c. Level of agreement: 100% 361 
 362 
Current evidence and literature: 363 
Battaglia et al.24 showed that, one year after biofeedback therapy, only 20% of 364 
patients with STC maintained a beneficial effect compared to 50% of patients with 365 
pelvic floor dyssynergia (PFD). In the short term (three-month assessment), both 366 
groups showed a significant improvement in abdominal pain, straining, number of 367 
evacuations/week and laxative use. The less effective biofeedback therapy in STC 368 
may be due to more complex pathophysiology and multiple involved factors like 369 
impairment of propulsive activity25 as well as physiologic reflexes26 not only in the 370 
most distal part of the bowel like in PFD. As not only therapy but also the underlying 371 
pathophysiology might be different in FC, PFD should be excluded. 372 
 373 
Future research/unmet needs: 374 
Pathophysiological studies that can discriminate/predict modifiable and innate factors 375 
of FC are needed. 376 
377 
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DIAGNOSTIC APPROACH 378 
CLINICAL APPROACH AND BASIC EXPLORATIONS 379 
Statement 10: The diagnosis of constipation can be made mainly on symptoms 380 
alone. Objective testing can be performed if considered necessary to identify 381 
underlying pathophysiological mechanisms 382 
a. Level of evidence: Very low 383 
b. Recommendation: Strong 384 
c. Level of agreement: 100 % 385 
 386 
Current evidence and literature: 387 
Despite very low evidence, most consensus guidelines agree that the diagnosis of 388 
constipation in the clinical setting is mainly made on the basis of symptoms alone.5, 6, 389 
27-30 A US survey showed that the most frequent symptoms of chronic constipation 390 
were straining, hard stools, abdominal discomfort, bloating, infrequent bowel 391 
movements and feeling of incomplete evacuation after bowel movement.31 Hence, 392 
the guidelines underscore the importance of a careful history assessing the presence 393 
of these symptoms as well as their duration and progression. Specific validated 394 
questionnaires, like the Patient Assessment of Constipation-Symptoms (PAC-SYM) 395 
questionnaire or the Bristol stool scale can be used for the clinical evaluation of the 396 
patient with constipation.32 Objective testing is recommended when the physician 397 
considers it necessary to rule out organic disease, i.e. if alarm symptoms are 398 
present, or in refractory cases to identify underlying pathophysiology that may help 399 
guide treatment.  400 
 401 
Statement 11: The most frequent symptoms of chronic constipation are 402 
straining and hard stools 403 
a. Level of evidence: Moderate 404 
b. Recommendation: Strong 405 
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c. Level of agreement: 100%  406 
Current evidence and literature: 407 
The prevalence of specific symptoms in chronic constipation has been addressed in 408 
systematic reviews and meta-analyses.5, 6, 27-30, 33-38 These studies have agreed that 409 
straining and hard stools are the most frequent symptoms of chronic constipation. 410 
 411 
Statement 12. For diagnosis of functional constipation, the Rome IV criteria are 412 
recommended.  413 
a. Level of evidence: Not applicable 414 
b. Recommendation: Strong 415 
c. Level of agreement: 100 %  416 
 417 
Current evidence and literature: 418 
The Rome IV criteria include the following symptoms: a. Straining; b. Hard stools 419 
(Bristol 1-2); c. Sensation of incomplete evacuation; d. Sensation of anorectal 420 
obstruction; e. Need for manual manoeuvres to facilitate evacuation; and f. Less than 421 
3 spontaneous bowel movements per week.6 Despite differences in the prevalence of 422 
each individual symptom, the authors chose to maintain the 25% rule (symptom 423 
present in 25% of stool movements) for all symptoms to facilitate the use of the 424 
criteria in the clinical setting.28, 30, 37, 39 However, in the clinical setting, especially in 425 
pragmatic primary care, patients can be diagnosed with FC with no awareness of 426 
formal criteria.. 427 
 428 
Statement 13: For the diagnosis of chronic constipation, patients must not 429 
fulfil criteria for IBS. This means not having abdominal pain as the primary 430 
symptom. 431 
a. Level of evidence: Low 432 
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b. Recommendation: Weak 433 
c. Level of agreement: 92 %  434 
 435 
Current evidence and literature: 436 
The differentiation between IBS-C and FC is an area of major controversy. Most 437 
authors consider that the presence of abdominal pain is the cornerstone for 438 
differentiating between both disorders. However, as recognised in the Rome IV 439 
criteria, functional bowel disorders are a spectrum of disorders with great overlap and 440 
no clear or definite borders that differentiate them in clinical practice. Hence, bloating 441 
and abdominal pain is often seen in patients with constipation. In line with recent 442 
recommendations, we believe that the diagnosis of IBS should be considered only 443 
when abdominal pain is the main symptom in a patient with constipation, but not 444 
when it is just a secondary accompanying symptom.6, 27, 40-42 445 
 446 
Future research/unmet needs: 447 
There is a lack of objective biological markers that can differentiate between FC and 448 
IBS-C.  449 
 450 
Statement 14: In constipated patients on opioid medication, opioid-induced 451 
constipation (OIC) should be considered as a differential diagnosis 452 
a. Level of evidence: Moderate 453 
b. Recommendation: Strong 454 
c. Level of agreement: 92% 455 
 456 
Current evidence and literature: 457 
Constipation is a common side effect of opioid use that can affect up to 81% of 458 
patients, even with the concomitant use of laxatives.43 Due to the increasing use of 459 
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opioids in western countries, there is a strong need to rule out the use of opioids in 460 
patients with constipation, especially considering that opioid consumption is not 461 
always reported by patients.6, 28, 37, 43-45 462 
However, in these patients, other aspects related to the illness requiring opiates such 463 
as anorexia, immobility and concomitant treatments have also to be considered. 464 
Owing to receptor downregulation the opiate effect on both pain and the bowel 465 
declines over time and finally, the best test of whether opiates are truly responsible is 466 
an improvement on discontinuing therapy or response to naloxegol.  467 
 468 
 469 
Statement 15: A simple blood test should be performed in the evaluation of 470 
patients with constipation to identify secondary causes. 471 
a. Level of evidence: Very low 472 
b. Recommendation: Strong 473 
c. Level of agreement: 100 %.  474 
 475 
Current evidence and literature: 476 
Observational studies have identified thyroid- and calcium-related disorders as 477 
potential causes of constipation. Consequently, several consensus reports6, 28, 29, 33-36 478 
emphasise the relevance of a simple blood test including glucose, calcium and 479 
thyroid-stimulating hormone (TSH) in the evaluation of patients with constipation.46 480 
 481 
 Future research/unmet needs 482 
Cost effectiveness analysis on the value of blood test in patients without other 483 
symptoms suggestive of endocrine or metabolic disorders. 484 
 485 
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Statement 16: The Bristol Stool Form Scale (BSFS) can be used to record stool 486 
consistency in patients with constipation. 487 
a. Level of evidence: Moderate 488 
b. Recommendation: Strong 489 
c. Level of agreement: 100% 490 
 491 
Current evidence and literature: 492 
The usefulness of the BSFS in assessing constipation has been demonstrated in 493 
different studies. Lewis at al.26 showed concordance between the whole gut transit 494 
time objectively measured with radiopaque markers and the stool form score. The 495 
BSFS has been proposed as a reliable indicator of FC that may be particularly useful 496 
in assessing patients with some discrepancy between the frequency of bowel 497 
movements and stool hardness.32, 46, 47 Even though other aspects related to 498 
individual motor patterns or efficiency of water absorption could influence stool form, 499 
the authors agree that the BSFS is a useful but underused tool for clinical practice. 500 
 501 
Statement 17: Physical examination in patients with FC should always include 502 
digital rectal examination (DRE) 503 
a. Level of evidence: Moderate 504 
b. Recommendation: Strong 505 
c. Level of agreement: 100 % 506 
 507 
Current evidence and literature: 508 
Digital rectal examination (DRE) is a very important physical examination in the 509 
diagnosis of a patient with constipation. DRE can detect stool in the rectal vault, 510 
anorectal masses, haemorrhoids, anal fissures, rectal prolapse, and rectoceles that 511 
may cause constipation. DRE should be performed at rest, and asking the patient to 512 
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strain, to identify alterations such as dyssynergic anal contraction, excessive or 513 
defective anal descent, or other structural abnormalities that are not apparent at 514 
rest.48-53 However, due to the non-physiological conditions of the DRE, the final 515 
diagnosis of an evacuation disorder needs confirmation with functional studies. 516 
 517 
FUNCTIONAL STUDIES 518 
Statement 18: Functional testing in chronic constipation is recommended 519 
(where available) when first-line therapeutic measures have failed to improve 520 
symptoms.  521 
a. Level of evidence: Very low 522 
b. Recommendation: Strong 523 
c. Level of agreement: 100 % 524 
 525 
Current evidence and literature: 526 
Patients consulting for constipation should initially be empirically managed with 527 
lifestyle and dietary modifications, withdrawal (or reduction) of constipating 528 
medications and fibre supplementation.54 Most patients will respond adequately to 529 
these first-line therapeutic measures, and therefore specialised diagnostic evaluation 530 
should only be offered to patients in whom these measures fail to improve 531 
symptoms.55 Advanced functional testing is not available in all settings; however, 532 
procedures such as the balloon expulsion test (BET) and whole gut transit evaluation 533 
using radiopaque markers may be performed even when resources are limited.54 534 
 535 
Future research/unmet needs:  536 
First-line measures are effective in most patients, but adherence is generally low. 537 
Increasing compliance to diet and laxatives is an area for improvement. 538 
 539 
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 540 
Statement 19: Aetiological factors to be evaluated in chronic constipation are: 541 
defecatory function (abdominal compression/anal relaxation), intrinsic 542 
innervation by rectoanal inhibitory reflex (minimal incidence of primary 543 
neuropathies and Hirschsprung’s disease in adults, but increasing incidence 544 
of Chagas disease), colonic transit, and rectal sensation/compliance (in 545 
neurological diseases and severe cases). 546 
a. Level of evidence: Low 547 
b. Recommendation: Strong 548 
c. Level of agreement: 100 % 549 
 550 
Current evidence and literature: 551 
The purpose of functional testing is to determine the pathophysiological mechanisms 552 
of constipation and subsequently guide therapeutic measures.46 Tests evaluating 553 
defecatory function, specifically anorectal manometry (ARM) and BET should be the 554 
initial investigations, since evacuation disorders are highly prevalent and may be less 555 
likely to respond to first-line therapeutic measures.56 Other dynamic tests, generally 556 
not as widely available as ARM and BET, but providing valuable complementary 557 
information on defecatory function, include defecography, electromyography and 558 
ultrasonography. None of the tests are individually sufficient to diagnose a defecation 559 
disorder, and therefore at least two abnormal evacuation tests are considered 560 
necessary to diagnose a functional defecation disorder (FDD).57 561 
Other primary aetiological factors of chronic constipation to be evaluated are intrinsic 562 
innervation and colonic transit. In addition, functional testing is also useful to 563 
diagnose the consequences of chronic constipation: abnormal rectal compliance and 564 
perineal damage. 565 
 566 
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Future research/unmet needs:  567 
Test protocols should be standardised, including instructions to the patient, which 568 
have been shown to significantly influence the outcome.58 Studies evaluating ARM in 569 
healthy volunteers have shown dyssynergic patterns, which have been attributed to 570 
the non-physiological position during the test, embarrassment or fear of 571 
incontinence.59 572 
 573 
Statement 20:  Anorectal manometry evaluates defecatory function 574 
(coordination of abdominal compression and anal relaxation) and intrinsic 575 
innervation by the rectoanal inhibitory reflex (primary aetiologic factors) as 576 
well as sphincter function and rectal sensitivity/compliance. 577 
a. Level of evidence: High 578 
b. Recommendation: Strong 579 
c. Level of agreement: 100 % 580 
 581 
Current evidence and literature: 582 
Evaluation of the defecatory manoeuvre during ARM should demonstrate adequate 583 
coordination between the increase in intrarectal pressure and anal relaxation. Weak 584 
abdominal compression and inadequate relaxation of the anal canal are the 585 
physiological basis of DD, an important cause of functional constipation.60 586 
The rectoanal inhibitory reflex (RAIR) depends on the intrinsic innervation of the gut. 587 
An abnormal RAIR is typically found in Hirschsprung’s disease but may also be 588 
detected in other visceral neuropathies such as Chagas disease.61 Technical aspects 589 
are important when evaluating the RAIR. A common pitfall is insufficient rectal 590 
distension in patients with megarectum, which may be overcome by using a barostat 591 
to obtain sufficient pressure.62 592 
 593 
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Future research/unmet needs: 594 
There is significant discrepancy between methods in data acquisition, analysis and 595 
interpretation of ARM; there is a need for expert international cooperation to 596 
standardise ARM.63 597 
 598 
Statement 21: High-resolution manometry is as useful as conventional 599 
manometry, and may be helpful in the interpretation of the defecatory 600 
manoeuvre 601 
a. Level of evidence: Moderate 602 
b. Recommendation: Strong 603 
c. Level of agreement: 100 % 604 
 605 
Current evidence and literature: 606 
High-resolution manometry obtains circumferential pressure measurements of the 607 
anal canal and distal rectum. Unlike conventional manometry, it may detect 608 
asymmetry of the anal pressures at rest or during squeeze.64 In addition, 609 
topographical colour-contour plots may facilitate interpretation of the defecatory 610 
manoeuvre compared to conventional manometry.65 However, no significant 611 
differences in the diagnosis of DD have been detected when directly compared.66-68 612 
 613 
 614 
 615 
Statement 22: An abnormal balloon expulsion test is indicative of an impaired 616 
defecatory manoeuvre and may predict a better response to biofeedback 617 
therapy. 618 
a. Level of evidence: Moderate 619 
b. Recommendation: Strong 620 
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c. Level of agreement: 100 % 621 
 622 
Current evidence and literature: 623 
The BET measures the capacity and time to evacuate an air- or water-filled balloon 624 
from the rectum. This test has been shown to be abnormal in a high proportion of 625 
patients with an evacuation disorder,69 but as mentioned previously, is not diagnostic 626 
as a single test. In fact, agreement with disordered defecation measured with ARM is 627 
relatively low. Indeed, the BET may be normal in patients with DD who are able to 628 
compensate by excessive straining. The BET has been shown to predict response to 629 
biofeedback therapy,70, 71 although this finding is not uniform in all studies.72 630 
 631 
Future research/unmet needs:  632 
There is considerable disagreement between the tests of evacuatory function; 633 
diagnostic criteria for impaired defecatory function should be established.73 634 
 635 
Statement 23: Rectal compliance is evaluated by the pressure/volume 636 
relationship with an air-filled rectal bag. Patients with constipation may have 637 
higher rectal compliance than controls. 638 
a. Level of evidence: Low 639 
b. Recommendation: Strong 640 
c. Level of agreement: 100 % 641 
 642 
Current evidence and literature: 643 
Rectal compliance may be measured by evaluating the pressure/volume relationship 644 
during progressive rectal distension with a balloon. For this purpose, the use of a 645 
barostat is useful because it allows direct measurement of rectal capacity at fixed 646 
pressure levels.74 Increased rectal compliance may be associated with chronic 647 
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constipation, particularly in children with megarectum.75 Nevertheless, in paediatric 648 
constipation, increased rectal compliance has not been shown to increase treatment 649 
failure.76, 77 650 
 651 
Statement 24: Oro-anal transit is most commonly measured by radiopaque 652 
markers; interpretation of slow colonic transit is not reliable in the case of 653 
functional or organic outlet obstruction. 654 
a. Level of evidence: Moderate 655 
b. Recommendation: Strong 656 
c. Level of agreement: 91 % 657 
 658 
Current evidence and literature: 659 
The radiopaque marker (ROM) test is the current standard test for the evaluation of 660 
oro-anal transit, with the advantages of low cost, simplicity and wide availability. 661 
Unfortunately, protocols are not standardised, and the technique varies widely 662 
between centres. Alternatively, the Smart Pill test and scintigraphy may be used to 663 
evaluate colonic transit times, and have been shown to correlate well with the ROM 664 
test.78 665 
STC is characterised by a delayed colonic transit time. However, transit time may 666 
also be delayed in patients with important faecal retention or with an evacuation 667 
disorder, so these must be excluded to identify patients with STC alone.79-81 In 668 
patients with FC, transit times have been shown to correlate well with stool 669 
consistency/form but poorly with stool frequency and associated symptoms.47, 82 670 
 671 
Future research/unmet needs: 672 
The procedure should be standardised.  673 
 674 
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RADIOLOGICAL STUDIES 675 
Statement 25: The recommended test name is 'defecography' (barium or 676 
magnetic resonance [MR]) 677 
a. Level of evidence: Very low 678 
b. Recommendation: Strong 679 
c. Level of agreement: 100 %. 680 
 681 
Current evidence and literature:  682 
The terminology is far from being universally accepted, given the numerous technical 683 
variations and the plethora of synonyms for defecography employed since its 684 
conception83: ‘cineradiographic defecography’,84 ‘cinedefecography’,85 ‘evacuating’86 685 
or ‘evacuation proctography’,21 ‘defecation’87 or ‘defecating proctography’88, 686 
‘videodefecography’,89 and ‘videoproctography’.90 However, the term ‘defecography’ 687 
has been most commonly reported (~60% of all published articles); it was initially 688 
proposed by Mahieu91 to more clearly imply that the physiological act of defecation is 689 
examined in dynamic conditions analogous to the investigation of deglutition or 690 
micturition.  691 
 692 
Future research/unmet needs: 693 
One of the principle challenges will be to promote standardisation of the language 694 
and the technique so that results are transferrable between institutions. 695 
 696 
Statement 26: Normative data for structural and functional parameters are 697 
available for both barium and MR defecography, but are limited in their scope, 698 
particularly for MR. There may be considerable overlap in findings between 699 
health and disease 700 
a. Level of evidence: Moderate 701 
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b. Recommendation: Strong 702 
c. Level of agreement: 100 % 703 
 704 
Current evidence and literature: 705 
A total of only four studies have been conducted in ≥40 healthy subjects, two using 706 
barium [X-ray] defecography (BD)92, 93 and two using MR defecography (MRD).94, 95 707 
Regardless of the technique, a consistent criticism of defecography is the 708 
acknowledged overlap between health and disease,92 hampered by a paucity of 709 
normative data, which challenges our ability to define ‘true’ (pathologic) 710 
abnormalities.  711 
 712 
Future research/unmet needs; 713 
The optimal technique for BD and MRD remains to be defined and should be subject 714 
to a Working Group initiative. Normative values are only applicable to specific 715 
protocols, and are mostly derived from female patients (for MRD, data existing for 716 
males are derived from a cohort of only 25 subjects in one study94). 717 
 718 
Additional comments: 719 
Normative data sets have provided evidence of truly pathologic findings (i.e. those 720 
not seen in health), such as large rectoceles, high-grade intussuscepta and 721 
enteroceles (whole gut or oro-anal).96 722 
 723 
Statement 27: Adherence to standardised study protocols is necessary 724 
a. Level of evidence: Low 725 
b. Recommendation: Strong 726 
c. Level of agreement: 100 % 727 
 728 
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Current evidence and literature: 729 
The prevalence of structural and functional abnormalities detected by defecography 730 
is high, but varies considerably across studies, with high heterogeneity depending on 731 
technical protocol variations and diagnostic criteria used. For example, several 732 
different cut-offs have been used to define: a) dynamic perineal descent (ranging 733 
from 2 to 6 cm)97, 98; b) the magnitude of the infolding for rectal intussuscepta (any 734 
fold “more than a wrinkling of the mucosa”99; ≥3 mm100; >4 mm85, 101; or >1 cm98, 102); 735 
and c) severity of rectocele based on maximum depth: 2 cm94, 100, 103-108; 2.5 cm109; 3 736 
cm85, 90, 110, 111; or 4 cm.73, 112, 113 737 
 738 
Future research/unmet needs:  739 
As above, standardisation of protocols is a prerequisite for obtaining results that are 740 
robust, reproducible and easily transferable between institutions. 741 
 742 
Statement 28: Barium defecography is indicated in patients with refractory 743 
symptoms of an evacuation disorder, and can accurately delineate several 744 
rectal structural abnormalities that often co-exist 745 
a. Level of evidence: Moderate 746 
b. Recommendation: Strong 747 
c. Level of agreement: 100 % 748 
 749 
Current evidence and literature: 750 
The prevalence of pathologic high-grade (i.e. Oxford III and IV) rectoanal 751 
intussusceptions and external rectal prolapse (i.e. Oxford grade V) on BD is 23.7% 752 
(95% CI, 16.8-31.4; based on 13 studies) and 5.3% (95% CI, 3.1-8.0; based on 16 753 
studies), respectively. The prevalence of large (>4 cm) pathologic rectoceles is 754 
15.9% (95% CI, 10.4-22.2; based on 9 studies). Enterocele and excessive perineal 755 
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descent are observed in 16.8% (12.7-21.4) and 44.4% (36.2-52.7) of patients, 756 
respectively96 (numerous references omitted for the sake of brevity). 757 
 758 
Future research/unmet needs: 759 
As per the points listed above, optimum cut-offs to define true abnormalities (both in 760 
terms of anatomical features, and impaired evacuation) need to be refined, based on 761 
standardised protocols. 762 
 763 
Statement 29: Amongst commonly performed investigations for symptoms of 764 
an evacuation disorder (e.g. ARM, BET, sonography), barium defecography 765 
can be considered the gold standard for assessment of structural rectal 766 
abnormalities 767 
a. Level of evidence: Low 768 
b. Recommendation: Strong 769 
c. Level of agreement: 100 % 770 
 771 
Current evidence and literature: 772 
BD is considered the gold standard for the assessment of posterior compartment 773 
disorders, given its capability to dynamically evaluate the rectum during simulated 774 
defecation.109 Its particular advantage over BET and manometry is that it enables 775 
characterization of structural abnormalities.73, 92 BET and manometry are, de facto, 776 
unable to provide such information. A total of four studies (including ≥40 subjects) 777 
have used BD as the reference standard to assess the diagnostic yield of other 778 
imaging modalities (i.e. echodefecography114, 115 and dynamic transperineal 779 
ultrasound116, 117) in diagnosing posterior pelvic floor compartment disorders. 780 
 781 
Future research/unmet needs: 782 
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There is considerable disagreement between the results of various tests used to 783 
diagnose evacuation disorders. Diagnosis is test-dependent, which impacts upon 784 
patient management. This highlights the need for a reappraisal of both diagnostic 785 
criteria, and what represents the ‘gold standard’ investigation. There is also further 786 
scope for research in comparing the results of barium versus MR defecography. 787 
 788 
Statement 30: There is no single gold standard investigation for diagnosis of a 789 
‘functional’ evacuation disorder. Nevertheless, defecography can identify 790 
specific causes (e.g. ineffective expulsive force, non-relaxing puborectalis etc. 791 
[terminology inconsistently reported]) which may guide treatment 792 
a. Level of evidence: Low 793 
b. Recommendation: Weak 794 
c. Level of agreement: 100 %. 795 
 796 
Current evidence and literature: 797 
In defecography, the diagnosis of a functional abnormality is made using three 798 
possible features, originally described by Mahieu et al.,118 either combined or in 799 
isolation: a) poor opening of the anorectal angle (secondary to poor relaxation or 800 
indeed ‘paradoxical’ contraction of the puborectalis muscle); b) poor anal sphincter 801 
relaxation; and c) incomplete and/or prolonged evacuation based on percentage of 802 
contrast expelled and/or time taken, respectively. Diagnostic criteria and prevalence 803 
of functional abnormalities have been provided in 42 studies of ≥40 constipated 804 
patients, based on either ‘a’ (n = 22)101, 103, 104, 116, 119-136; ‘b’ (n = 2)110, 137; ‘c’ (n = 2)138, 805 
139; ‘a+b’ (n = 4)97, 112, 140, 141; ‘a+c’ (n = 7)85, 86, 114, 142-145; ‘b+c’ (n = 1)146; or ‘a+b+c’ (n = 806 
4).115, 147-149 Quantitative meta-analysis of these studies, including four comparative 807 
(BD vs MRD) studies, shows a pooled prevalence of 24.1% (95% CI, 20.2-28.4) for 808 
BD and 25.9 (14.1-39.6) for MRD.96 809 
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 810 
Future research/unmet needs: 811 
There is a need for prospective studies designed to evaluate the utility and cost-812 
effectiveness of different diagnostic modalities to tailor management of constipation, 813 
as well as to determine predictors of response to biofeedback therapy. 814 
 815 
Statement 31: Barium defecography is useful in evaluating the outcome of 816 
surgical interventions for structural rectal abnormalities, particularly in 817 
patients with ongoing or recurrent symptoms 818 
a. Level of evidence: Low 819 
b. Recommendation: Weak 820 
c. Level of agreement: 100 % 821 
 822 
Current evidence and literature: 823 
Three studies have used BD to assess outcomes of stapled transanal rectal 824 
resection (STARR).150-152 One study compared the results of biofeedback retraining, 825 
botulinum toxin type A injection and partial division of puborectalis (PDPR) in a 826 
randomised study of 60 patients with anismus.153 827 
 828 
Future research/unmet needs: 829 
Defecography is widely used by the surgical community to direct surgical 830 
management in patients with constipation/evacuation disorder, where the operating 831 
procedure is directed to reversal of demonstrable posterior compartment 832 
abnormalities (e.g. rectocele, high grade intussusception) that are consistent with 833 
presentation of symptoms. However, no randomised controlled trials (RCT) or 834 
prospective stratified medicine studies are currently available. Such studies are 835 
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required now more than ever, given that litigation and intense media scrutiny have 836 
forced surgeons to rigidly objectify their motivation for offering surgery. 837 
 838 
Statement 32: MR defecography is indicated in patients with refractory 839 
symptoms of an evacuation disorder and has the advantage of routinely 840 
evaluating all pelvic compartments in those with suspected multi-841 
compartmental structural defects. However, comparative data with barium 842 
defecography is currently limited 843 
a. Level of evidence: Low 844 
b. Recommendation: Strong 845 
c. Level of agreement 100 % 846 
 847 
Current evidence and literature: 848 
A multiplanar, diagnostic assessment of the anterior, middle and posterior 849 
compartments is possible with MRD. Five studies, comprising ≥40 study subjects, 850 
have compared BD to MRD.105, 108, 109, 154, 155 BD represented the reference standard 851 
in all studies, except one that adopted the results obtained from the joint analysis of 852 
BD and MRD as reference.109 None of these studies followed the Standards for 853 
Reporting Diagnostic Accuracy (STARD) guidelines. 854 
 855 
Future research/unmet needs: 856 
Well-designed diagnostic test accuracy studies following STARD criteria are needed. 857 
 858 
Statement 33: MR and barium defecography are complementary and may 859 
provide additional diagnostic information when either one is equivocal or 860 
incomplete 861 
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a. Level of evidence: Low 862 
b. Recommendation: Strong 863 
c. Level of agreement: 100 % 864 
 865 
Current evidence and literature: 866 
Compared to BD, MRD allows a thorough assessment of all pelvic floor organs. 867 
However, in centres where MRD is the standard test, patients who fail to evacuate 868 
should also undergo BD or significant pathology will be missed.154 869 
 870 
Future research/unmet needs: 871 
Further well-designed comparative studies are required. 872 
 873 
Statement 34: Barium defecography is likely to be superior to MR 874 
defecography in detecting structural posterior pelvic compartment 875 
abnormalities leading to obstructed defecation 876 
a. Level of evidence: Moderate 877 
b. Recommendation: Weak 878 
c. Level of agreement: 100 % 879 
 880 
Current evidence and literature: 881 
Pooled results from the five studies (each comprising ≥40 study subjects) that have 882 
compared BD to MRD105, 108, 109, 154, 155 show that BD is superior to MRD in the 883 
detection of intussusception (pooled prevalence: 57.8% vs. 37.8%; OR, 1.52 [95% CI 884 
1.12-2.14, p=0.009]), although BD is associated with higher levels of embarrassment 885 
(qualitatively measured among patients), lower tolerance (54.3% vs. 30.0%; OR, 886 
1.73 [95% CI 1.14-2.62, p=0.008])96 and higher radiation exposure. 887 
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 888 
Future research/unmet needs: 889 
Well-designed diagnostic test accuracy studies following STARD criteria are required 890 
to confirm these findings. 891 
 892 
Additional comments: 893 
Concerns over the impact of patient test position on diagnostic yield for MRD (supine 894 
in closed-magnet configurations, considered non-physiological, vs upright in open-895 
magnet configurations) are yet to be adequately addressed. 896 
 897 
  898 
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TREATMENT 899 
LIFESTYLE AND GENERAL MEASURES 900 
Statement 35: Exercise has neither a positive nor a negative effect on 901 
constipation 902 
a. Level of evidence: Moderate 903 
b. Recommendation: Strong 904 
c. Level of agreement: 92 % 905 
 906 
Current evidence and literature: 907 
The literature does not delineate between functional constipation, chronic 908 
constipation or constipation per se. The data are conflicting but largely against 909 
benefit from exercise alone for constipation. One study of secondary school pupils 910 
(hence, largely normal subjects), which used bowel evacuations less than every two 911 
days as the criterion, concluded that constipation was associated with “insufficient” 912 
exercise or sedentary behaviour, and that this was dose-related to the amount of 913 
exercise taken.156 Similarly, in an education-led program in 35 women with chronic 914 
constipation, there was an improvement in their Bristol Stool scores and 915 
symptoms.157 However, the intervention was multi-layered, consisting of advice on 916 
diet, fluids and counselling. Conversely, in a study of healthy men over 35 days, 917 
intervention with experimentally-controlled bed rest, stool consistency and bowel 918 
symptoms was not influenced by physical inactivity.158 In another study conducted 919 
over six weeks in patients with idiopathic constipation, exercise levels and 920 
constipation were assessed. The level of exercise did not correlate with constipation 921 
indices and the conclusion was that physical activity to the extent considered “regular 922 
exercise” did not play a role in the management of idiopathic constipation.159 While 923 
data do indicate that GI transit times may be accelerated by exercise, this does not 924 
translate into outcomes in constipation. Although subjects with the slowest resting 925 
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transit rates may show the largest exercise effects in mouth-to-caecum transit time, 926 
this is not necessarily reflected in constipation symptoms.160, 161 927 
A review in 2011, which included two small randomised placebo-controlled trials and 928 
two cohort studies concluded that lifestyle modification to prevent or treat 929 
constipation was not substantiated by evidence.162 No systematic reviews exist for 930 
exercise and constipation, but exercise appears to be associated with a range of 931 
health benefits for people of all ages.159, 161, 163 A further review in 2011 confirmed 932 
conflicting evidence, again largely against the effect of exercise for constipation, with 933 
studies showing inconsistent effects.164. However, physical activity was noted to 934 
improve quality of life (QoL) in some subjects in some studies, and was associated 935 
with improved QoL and a decrease in symptom severity.165 936 
 937 
Future research/unmet needs: 938 
Evaluation of the level of exercise needed to maintain good general health and 939 
gastrointestinal health in individual people. 940 
 941 
Statement 36: In patients who are not dehydrated, additional fluid intake alone 942 
does not have a positive effect on constipation 943 
a. Level of evidence: Low 944 
b. Recommendation: Strong 945 
c. Level of agreement: 100 % 946 
 947 
Current evidence and literature: 948 
Medical advice frequently stresses the importance of “good” fluid intake for general 949 
health and, in particular, to manage constipation. There are no clear definitions of 950 
what constitutes an adequate or therapeutic level of fluid intake in people with 951 
constipation. Whilst there may be an association between “inadequate” fluid intake or 952 
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dehydration and constipation, there is a lack of evidence to support that increased 953 
fluids alone are of benefit.157, 163, 165 In a study of 833 elderly patients with a mean age 954 
of 74 years, it was noted that 71% already drank six or more glasses of water daily, 955 
and that there was no difference between them in terms of bowel symptoms and the 956 
29% who drank less fluids.166 In a 2011 review, only one RCT and one observational 957 
study was noted, with the RCT showing benefit from fluids only in the presence of 958 
additional fibre.162 Thus, the evidence in relation to increased fluid intake alone, as 959 
being positive for the management of constipation, is sparse. 960 
 961 
Future research/unmet needs: 962 
Larger, well-defined interventional studies should be done to provide data on 963 
appropriate intake for patients with constipation. 964 
 965 
Statement 37. Dietary fibre alone within the normal (regular) diet helps 966 
functional constipation. 967 
a. Level of evidence: Low 968 
b. Recommendation: Weak 969 
c. Level of agreement 92 % 970 
 971 
Current evidence and literature: 972 
This section relates to normal or regular intake of dietary components, essentially 973 
fibre, and does not relate to therapeutic supplements. However, much of the 974 
literature relates to fibre supplements and laxatives, and there is a paucity of data 975 
about lifestyle dietary measures geared to FC. A 2011 review concluded that, whilst 976 
increasing dietary fibre may help constipation caused by fibre deficiency, it should 977 
not be assumed that fibre deficiency is the main source of the problem.157 978 
Consuming a high fibre diet alone may not be as effective as combining it with 979 
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increased fluid intake. The overall evidence for increased dietary fibre (as opposed to 980 
recommended or prescribed fibre) is weak, although the effect may be enhanced if 981 
increased fluids are included.157, 162, 165, 167  982 
 983 
Future research/unmet needs: 984 
Interventional and observational studies in patients are needed.  985 
 986 
Statement 38: Overall lifestyle measures may be of value in some patients to 987 
improve constipation, quality of life and contribute towards better health 988 
a. Level of evidence: Moderate 989 
b. Recommendation: Strong 990 
c. Level of agreement: 100 % 991 
 992 
Current evidence and literature: 993 
With regard to overall lifestyle modification (combined factors), most studies consist 994 
of interventions or studies of fibre intake, fluids and exercise, but some also have 995 
additional factors such as counselling or individualised care. The effect of each of 996 
these is difficult to separate out. For example, an Egyptian study of 23 elderly 997 
patients with FC included group discussions about dietary patterns, fluid intake, 998 
physical activity and the use of laxatives.168 There was no control group, but the 999 
lifestyle modification education significantly reduced the severity of the FC and 1000 
recorded improvements in QoL. Combined with data from other studies, this 1001 
suggests that there is overall benefit from a combination of lifestyle measures, both 1002 
in constipation as well as in the QoL measures.165, 167 To this can be added the 1003 
benefits from a more active lifestyle in terms of general health. Whilst the data are 1004 
not robust, this would seem a reasonable approach in the practical management of 1005 
patients. 1006 
41 
 
 1007 
Future research/unmet needs: 1008 
More studies are needed on overall lifestyle and gastrointestinal health. 1009 
 1010 
BULKING AGENTS & OSMOTIC LAXATIVES 1011 
Statement 39: Bulking agents, in particular soluble fibre, are effective in the 1012 
management of chronic constipation 1013 
a. Level of evidence: Moderate 1014 
b. Recommendation: Strong 1015 
c. Level of agreement: 100 % 1016 
 1017 
Current evidence and literature: 1018 
Despite the fact that bulking agents, in the form of either soluble or insoluble fibre, 1019 
have relatively little support from large RCTs in patients with chronic constipation, 1020 
these agents are often recommended as first-line treatment options for patients with 1021 
chronic constipation. This is influenced by the safety and low cost of this approach, 1022 
as well as some efficacy data from trials, together with long-standing clinical 1023 
experience with these agents. In a systematic review evaluating the effects of fibre in 1024 
the management of chronic idiopathic constipation, only six RCTs were found to be 1025 
eligible: four used soluble fibre (three psyllium, one inulin and maltodextrin) and two 1026 
used insoluble fibre (one bran, and one fibre-rich rye bread). Soluble fibre led to 1027 
improvements in global symptoms (86.5% vs. 47.4%), straining (55.6% vs. 28.6%), 1028 
pain on defecation, and stool consistency, an increase in the mean number of stools 1029 
per week (3.8 stools per week after therapy compared with 2.9 stools per week at 1030 
baseline), and a reduction in the number of days between stools. In particular, the 1031 
effect of psyllium was convincing with a Number-Needed-to-Treat (NNT) of 2 (95% 1032 
CI 1.6 – 3), and with no statistically significant heterogeneity between the three 1033 
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psyllium studies.169 Evidence for any benefit of insoluble fibre was conflicting, mainly 1034 
based on small patient numbers and few eligible studies. As a follow-up of this 1035 
systematic review, the American College of Gastroenterology (ACG) recommended, 1036 
based on these six trials, that fibre and soluble fibre in particular are effective in the 1037 
management of chronic constipation.8 Soluble and insoluble fibre are also frequently 1038 
used in patients with IBS, but the status of fibre in general in IBS is far from 1039 
straightforward.169-175 Insoluble fibre may exacerbate symptoms and provide little 1040 
relief in patients with IBS, but soluble fibre and psyllium, in particular, seem to 1041 
provide relief in this condition.176-178 These latter effects appear to relate to the relief 1042 
of constipation, which further supports the use of soluble fibre in patients with 1043 
constipation, either FC or IBS-C. 1044 
 1045 
Future research/unmet needs: 1046 
Large, high-quality trials using modern clinical trial methodology are needed. 1047 
 1048 
Statement 40: The usefulness of bulking agents, in particular insoluble fibre, in 1049 
patients with chronic constipation is limited by adverse events, particularly 1050 
bloating, distension, flatulence, and cramping 1051 
a. Level of evidence: Moderate 1052 
b. Recommendation: Strong 1053 
c. Level of agreement: 100 % 1054 
 1055 
Current evidence and literature: 1056 
Bulking agents, e.g. psyllium, bind water and prevent absorption of water from 1057 
the lumen. This leads to increased small bowel water and increased colonic 1058 
volumes.179 These effects can explain both the positive effects of bulking 1059 
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agents, i.e. increased stool frequency, and potential side effects.  Adverse 1060 
events, particularly bloating, distension, flatulence, and cramping may limit the use of 1061 
insoluble fibre, especially if increases in fibre intake are not introduced gradually.8, 169-1062 
178, 180 1063 
 1064 
Future research/unmet needs: 1065 
Strategies to use fibre to reduce side effects should be defined, as well as 1066 
comparisons with other agents used to treat constipation. 1067 
 1068 
Statement 41: Saline laxatives, especially polyethylene glycol (PEG), are 1069 
effective in treating symptoms of constipation in patients with chronic 1070 
constipation 1071 
a. Level of evidence: Strong 1072 
b. Recommendation: Strong 1073 
c. Level of agreement: 100 % 1074 
 1075 
Current evidence and literature:  1076 
The evidence supporting the usefulness of saline laxatives, especially polyethylene 1077 
glycol (PEG), is strong. There are several large, high quality trials supporting the fact 1078 
that PEG is superior to placebo in improving symptoms in patients with chronic 1079 
constipation, with a NNT of 3 (95% CI 2 – 4).8, 181-189 Moreover, a Cochrane analysis 1080 
also concluded that PEG is superior to lactulose in patients with chronic constipation, 1081 
resulting in more frequent stools, looser stools, and less abdominal pain. PEG also 1082 
increases the number of spontaneous complete bowel movements, improves stool 1083 
consistency, and reduces severity of straining, without clearly affecting abdominal 1084 
pain, in patients with IBS-C, further supporting its usefulness to treat constipation. 1085 
44 
 
The most common side effects with PEG are diarrhoea and abdominal pain, but not 1086 
all trials find these to be more common in patients treated with PEG compared to the 1087 
placebo group.  1088 
 1089 
Future research/unmet needs: 1090 
Direct head-to-head comparisons with newer agents treating constipation are 1091 
needed. 1092 
 1093 
Statement 42: Lactulose is efficacious in the treatment of patients with chronic 1094 
constipation 1095 
a. Level of evidence: Low 1096 
b. Recommendation: Weak 1097 
c. Level of agreement: 100 % 1098 
 1099 
Current evidence and literature:  1100 
Clinical experience suggests that the osmotic properties of the unabsorbed 1101 
mono/disaccharides and sugar alcohols lactulose, lactitol, mannitol and sorbitol 1102 
benefit patients with chronic constipation, but evidence from high quality RCTs 1103 
supporting this is largely absent. Few RCTs exist and these have a high risk of bias 1104 
and moderate heterogeneity between studies, but suggest a positive effect of 1105 
lactulose versus placebo in chronic constipation with a NNT of 4 (95% CI 2 – 7).8, 181, 1106 
190, 191 Moreover, side effects such as abdominal cramping and bloating limit their 1107 
clinical usefulness. Also dried plums, which contain sorbitol, but also dietary fibres 1108 
and polyphenols, may be useful for constipation. This was demonstrated in a 1109 
randomized controlled trial, where dried plums were found to be safe, palatable and 1110 
more effective than psyllium for the treatment of mild to moderate constipation.192 At 1111 
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least part of the effect on constipation may be explained by the sorbitol content, 1112 
which act as an osmotic laxative. 1113 
 1114 
Future research/unmet needs: 1115 
High quality trials assessing the effects of the unabsorbed mono/disaccharides and 1116 
sugar alcohols lactulose, lactitol, mannitol and sorbitol are needed, including 1117 
comparisons with newer agents for the treatment of constipation. 1118 
 1119 
STIMULANT LAXATIVES 1120 
Statement 43: Bisacodyl is effective in the management of chronic 1121 
constipation. 1122 
a. Level of evidence: Moderate 1123 
b. Recommendation: Strong 1124 
c. Level of agreement: 100 % 1125 
 1126 
Current evidence and literature:  1127 
Bisacodyl is a diphenyl methane derivative hydrolysed by intestinal and bacterial 1128 
enzymes to a deacetylated active metabolite that induces high amplitude propagative 1129 
contractions of the colon and stimulates intestinal secretion.193 It is usually given 1130 
orally at a dose of 5-10 mg daily in a coated tablet that dissolves in the colon to 1131 
ensure a local effect, or as a suppository given at a dose of 10 mg daily. In healthy 1132 
volunteers, bisacodyl significantly accelerated emptying of the ascending colon, 1133 
although overall transit was not modified.194 In 2005, a systematic review of the 1134 
literature found that stimulant laxatives, including bisacodyl, had a level III of 1135 
evidence and were rated as a grade C recommendation,195 while the American 1136 
College of Gastroenterology Chronic Constipation Task Force underlined that high-1137 
quality data were lacking to make a recommendation about the efficacy of stimulant 1138 
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laxatives for the management of chronic constipation.196 Since then, only one 1139 
randomized, double-blind placebo-controlled study comparing the efficacy of daily 1140 
use of bisacodyl in chronic constipation has been conducted. In this study, performed 1141 
in 368 patients with chronic constipation defined by Rome III criteria, oral bisacodyl at 1142 
10 mg once daily increased the frequency of both bowel movements and complete 1143 
spontaneous bowel movements over a 4-week period.  1144 
 1145 
Statement 44: The use of bisacodyl in patients with chronic constipation is 1146 
often well tolerated  1147 
a. Level of evidence: Moderate 1148 
b. Recommendation: Strong 1149 
c. Level of agreement: 100 % 1150 
 1151 
Current evidence and literature:  1152 
Constipation-related QoL was also improved in the bisacodyl group compared with 1153 
placebo.197 Of note, six adverse events leading to drug discontinuation were 1154 
recorded in the placebo-treated group, versus 44 in the bisacodyl-treated group, the 1155 
most frequent being diarrhoea and abdominal pain. However, the occurrence of 1156 
serious adverse events was similar (<2%) in both groups. A second randomised-1157 
double-blind placebo-controlled study showed the efficacy of bisacodyl (10 mg once 1158 
daily for 3 days) to acutely relieve chronic constipation by increasing the frequency of 1159 
bowel movements and softening stool consistency.197 An open-label RCT conducted 1160 
in two groups of patients with chronic constipation treated with either pyridostigmine 1161 
or bisacodyl showed that both treatments achieved an increase in bowel movements 1162 
per week compared to baseline, with greater efficacy with pyridostigmine compared 1163 
to bisacodyl.198 1164 
 1165 
Future research/unmet needs: 1166 
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Controlled studies evaluating the efficacy of bisacodyl in FC over 4 weeks of 1167 
treatment are lacking and should be conducted. Whether the association of bisacodyl 1168 
with an osmotic laxative is superior to bisacodyl alone or an osmotic laxative alone 1169 
has yet to be investigated.  1170 
 1171 
Statement 45: Sodium picosulfate is effective in the management of chronic 1172 
constipation, at least as a short-term treatment. 1173 
a. Level of evidence: Moderate 1174 
b. Recommendation: Strong 1175 
c. Level of agreement: 100 % 1176 
 1177 
Current evidence and literature:  1178 
Sodium picosulfate is a locally-acting stimulant laxative hydrolysed by the colonic 1179 
microflora into the same active form as bisacodyl. It therefore has a similar mode of 1180 
action to bisacodyl, including increased colon peristalsis and secretion. There is only 1181 
one randomised, double-blind placebo-controlled study comparing the efficacy of 1182 
sodium picosulfate in chronic constipation.199 This study was conducted in 367 1183 
patients with Rome III-defined FC allocated 2:1 to receive either sodium picosulfate 1184 
(10 mg/day) or placebo for 4 weeks. The number of complete spontaneous bowel 1185 
movements (CSBMs) increased from 0.9 to 3.4 per week in the sodium picosulfate 1186 
treated group compared with an increase from 1.1 to 1.7 per week in the placebo-1187 
treated group.  1188 
 1189 
Future research/unmet needs: 1190 
Controlled studies evaluating the efficacy of sodium picosulfate in FC over a 4-week 1191 
treatment period are lacking and should be conducted. Whether the association of 1192 
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sodium picosulfate with an osmotic laxative is superior to sodium picosulfate alone or 1193 
an osmotic laxative alone is yet to be investigated. 1194 
 1195 
Statement 46: The use of sodium picosulfate in patients with chronic 1196 
constipation is often well tolerated. 1197 
a. Level of evidence: Moderate 1198 
b. Recommendation: Strong 1199 
c. Level of agreement: 100 % 1200 
 1201 
Current evidence and literature:  1202 
Constipation-related QoL was also improved after treatment in the sodium 1203 
picosulfate treated group compared with placebo. Comparable to bisacodyl, 1204 
diarrhoea and abdominal pain were the most common adverse events reported 1205 
compared with placebo. The efficacy of sodium picosulfate was compared with 1206 
bisacodyl in an open-label RCT involving 144 patients with chronic constipation.200 1207 
After 4 weeks of treatment, sodium picosulfate and bisacodyl both achieved a 1208 
comparable number of bowel movements per week (3.2 in both groups).  1209 
 1210 
Statement 47: Anthraquinones, and particularly senna, are effective in the 1211 
management of chronic constipation 1212 
a. Level of evidence: Low 1213 
b. Recommendation: Weak 1214 
c. Level of agreement: 100 %  1215 
 1216 
Current evidence and literature:  1217 
This class of laxatives includes mainly sennosides A and B and cascara. Sennosides 1218 
are transformed by the colonic microbiota into active components201 They cannot be 1219 
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absorbed and are not excreted in breast milk. Clinical trials are sparse, and have 1220 
often been conducted in the geriatric population or in patients with OIC. In these 1221 
trials, the objective was often to demonstrate the additional benefit of combining 1222 
senna to a bulk or osmotic laxative. The available trials prove their efficacy for 1223 
increasing the number of stools or improving stool consistency. Senna provided more 1224 
improvement than bulk or osmotic laxatives,202-204 and obtained similar results to 1225 
magnesium hydroxide,205 sodium picosulfate,206 and even lubiprostone.207 1226 
 1227 
Future research/unmet needs: 1228 
Blinded controlled studies evaluating the efficacy of anthraquinones are still lacking 1229 
and should be performed.  1230 
 1231 
Statement 48: Anthraquinones, and particularly senna are often well tolerated 1232 
in patients with chronic constipation.  1233 
a. Level of evidence: Moderate 1234 
b. Recommendation: Weak 1235 
c. Level of agreement: 100 % 1236 
 1237 
Current evidence and literature:  1238 
Anthraquinones have been linked with the development of melanosis coli, which is a 1239 
brown pigmentation of the colonic mucosa due to collections of lipofuscin-containing 1240 
macrophages.208, 209 It is now established that this pigmentation has no clinical 1241 
significance.208 An increased risk of colorectal cancer has also been discussed. In a 1242 
prospective study of 84 577 females, no association between laxative use and 1243 
colorectal cancer was found.210 1244 
 1245 
PROKINETICS & SECRETAGOGUES 1246 
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Statement 49: The serotonin (5-HT)-4 agonist prucalopride has prokinetic 1247 
action in the entire gut, and is effective in the management of chronic 1248 
constipation, including conditions refractory to conventional laxatives. 1249 
a. Level of evidence: High 1250 
b. Recommendation: Strong 1251 
c. Level of agreement: 100 % 1252 
 1253 
Current evidence and literature:  1254 
The serotonin (5-HT)-4 agonist prucalopride has been shown to be effective in 1255 
severe chronic constipation refractory to laxatives, and has been approved in Europe 1256 
for this indication for several years.211-216 It is highly receptor-selective and has no 1257 
cardiologic side effects. Other related substances play no practical role in the 1258 
treatment of chronic constipation at this time; examples include cisapride, which is no 1259 
longer available as it had been associated with QT prolongation, torsades de pointes 1260 
and cardiac arrest, thought to be due to its binding and inactivation of  a potassium 1261 
channel encoded by the  hERG gene; mosapride (established only for the upper GI 1262 
tract); and molecules such as velusetrag (no current clinical trials available despite 1263 
positive data from an earlier phase-2 study) and naronaprid (currently being 1264 
evaluated); for review compare Prichard DO & Barucha AE, Recent advances in 1265 
understanding and managing chronic constipation. F1000Res. 2018 Oct 15;7. pii: 1266 
F1000 Faculty Rev-1640. doi: 10.12688/f1000research.15900.1. eCollection 2018. 1267 
PMID: 30364088.  1268 
Future research/unmet needs: 1269 
Predictors of response are poorly defined. In particular, the relevance of different 1270 
pathomechanism of constipation (e.g. slow vs. normal transit) has not been clarified. 1271 
51 
 
The potential therapeutic role of prucalopride in other segments of the GI tract should 1272 
be further elucidated. 1273 
 1274 
Statement 50: Acetylcholinesterase inhibitors exert prokinetic effects in the 1275 
intestine, but currently have no practical role in the management of chronic 1276 
constipation 1277 
a. Level of evidence: Moderate 1278 
b. Recommendation: Weak 1279 
c. Level of agreement: 100 % 1280 
 1281 
Current evidence and literature:  1282 
Acetylcholinesterase inhibitors exert prokinetic action by inhibiting degradation of 1283 
acetylcholine, thus amplifying its effects in the enteric nervous system (ENS) as well 1284 
as in GI smooth muscle. Distigmine (and related substances) have their use in (often 1285 
refractory, and usually acute or protracted) motility disturbances, such as colonic 1286 
acute pseudoabstruction, postoperative ileus, etc.217 On an individual basis they may 1287 
be useful in selected cases of CC refractory to other established treatments. Indeed, 1288 
a small trial reported similar efficacy as bisacodyl.198 Overall, they have limited 1289 
use in chronic constipation. This is also due to their low specificity, with effects on 1290 
both muscarinic and nicotinic receptors, and because they have been associated 1291 
with multiple systemic, secretory, and serious cardiologic side effects.218, 219 1292 
Acotiamide is a new acetylcholinesterase inhibitor with additional anti-muscarinic 1293 
effects, available in Japan and currently being evaluated in Europe and the USA for 1294 
functional dyspepsia220; there are no data for chronic constipation. 1295 
 1296 
Future research/unmet needs: 1297 
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Their therapeutic potential in defined subtypes of constipation disorders is not well 1298 
defined and thus they are possibly under-utilized. 1299 
 1300 
Statement 51: Peripherally Acting µ-Opioid Receptor Antagonists (PAMORA) 1301 
have prokinetic properties by reversing the inhibitory effects of µ-opioid 1302 
analgesics on GI motility, and are effective in the management of opioid-1303 
induced chronic constipation 1304 
a. Level of evidence: High 1305 
b. Recommendation: Strong 1306 
c. Level of agreement: 100 % 1307 
 1308 
Current evidence and literature:  1309 
Peripherally Acting µ-Opioid Receptor Antagonists (PAMORA) inhibit the peripheral 1310 
effects of µ-opioid analgesics on bowel functions such as reduced GI motility and 1311 
secretion, as well as increased fluid absorption.221-223 True PAMORA (naloxegol, 1312 
methylnaltrexone, alvimopan, naldemedine) do not pass the blood-brain barrier and 1313 
are effective in the treatment of OIC without affecting the central analgesic effects.224-1314 
234 The systemic opioid antagonist naloxone if administered as slow release formula 1315 
may also inhibit intestinal opioid effects with little/no systemic action due the high first 1316 
pass effect in the liver, it is available as a fixed combination tablet with oxycodone.235, 1317 
236 1318 
 1319 
Future research/unmet needs: 1320 
Since there is limited data on combination treatments, further studies should be 1321 
done. 1322 
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 1323 
Statement 52: Peripherally Acting µ-Opioid Receptor Antagonists (PAMORA) 1324 
have prokinetic properties even in the absence of opioid therapy and may 1325 
potentially be effective in constipation not caused by opioids 1326 
a. Level of evidence: Low 1327 
b. Recommendation: Weak 1328 
c. Level of agreement: 100 % 1329 
 1330 
Current evidence and literature:  1331 
A high quality RCT237 demonstrated that in healthy subjects the PAMORA alvimopan 1332 
not only reversed opioid-induced inhibition of small-bowel and colon transit, but also 1333 
significantly accelerated colonic transit in the absence of opioid co-treatment. These 1334 
findings suggest that µ-opiate mechanisms participate in the physiologic regulation of 1335 
colonic motility, independent of opioid-induced modulation. 1336 
 1337 
 1338 
Future research/unmet needs: 1339 
The therapeutic potential of PAMORA in chronic constipation subtypes not induced 1340 
by opioids should be investigated.  1341 
 1342 
Statement 53. The guanylate cyclase C receptor agonist linaclotide is effective 1343 
and safe in the management of chronic constipation and IBS-C 1344 
a. Level of evidence: High 1345 
b. Recommendation: Strong 1346 
c. Level of agreement: 92 % 1347 
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 1348 
Current evidence and literature:  1349 
Linaclotide acts as an oral guanylate cyclase C receptor agonist, increases 1350 
intracellular cyclic guanosine monophosphate (cGMP) levels, and thus fluid secretion 1351 
into the intestinal lumen, which in turn accelerates gastrointestinal transit velocity. At 1352 
a dose of 290µg/d it significantly improves chronic constipation with a RR of 1353 
response to treatment of 1.95 [1.3-2.9] and a NNT of 7. In addition, it has been 1354 
licensed as treatment for IBS-C as it also improves abdominal symptoms commonly 1355 
associated with CC, such as bloating or pain238, 239 due to decreasing effects on 1356 
visceral hypersensitivity.238, 239 Linaclotide may cause diarrhoea as its most frequent 1357 
side effect, but has a very low risk of major systemic adverse responses due to its 1358 
local action in the intestinal lumen and low bioavailability.181, 240 1359 
 1360 
Statement 54:  The chloride channel activator lubiprostone is effective in the 1361 
management of chronic constipation and IBS-C, but has limited availability in 1362 
the majority of European countries 1363 
a. Level of evidence: High 1364 
b. Recommendation: Strong 1365 
c. Level of agreement: 92 % 1366 
 1367 
Current evidence and literature:  1368 
Lubiprostone is a chloride channel activator and induces intra-intestinal water and 1369 
chloride secretion, and accelerates transit. In RCTs in patients with chronic 1370 
constipation and IBS-C, Lubiprostone was associated with significantly improved 1371 
symptoms222, 241-245 with a therapeutic benefit of 7.8%, and a NNT of 12.8 .246 1372 
Lubiprostone may cause nausea and has been suspected to promote abortion rates 1373 
55 
 
in animal studies due to its prostaglandin properties.222, 241-245 Hence, it is mostly used 1374 
as reserve medication, and has not been approved in most European countries so 1375 
far. 1376 
 1377 
Future research/unmet needs: 1378 
The optimal target group and side effects should be defined more clearly. Limited or 1379 
no availability in most European countries.  1380 
 1381 
BIOFEEDBACK THERAPY 1382 
STATEMENT 55: Biofeedback is the preferred treatment for constipation due to 1383 
functional defecation disorders whenever dedicated expertise is available, 1384 
regardless of abnormal bowel transit 1385 
a. Level of evidence: Moderate 1386 
b. Recommendation: Strong 1387 
c. Level of agreement: 100 % 1388 
 1389 
Current evidence and literature:  1390 
Biofeedback is a conditioning treatment where information about a physiological 1391 
process is converted to a simple signal to enable the patient to learn to control the 1392 
disordered function.247 Recently, instrumented biofeedback has been reported to 1393 
ameliorate symptoms and accelerate bowel transit by improved defecation effort in 1394 
over 70% of STC due to DD, while isolated STC did not benefit.79 This study provided 1395 
support for the specific therapeutic contribution of biofeedback therapy and heralded 1396 
three pivotal RCTs addressing its effectiveness in FDDs.248-250 These pivotal trials 1397 
were adequately sized and included only severe, refractory constipation due to DD 1398 
diagnosed by physiology testing, regardless of abnormal colon transit in most of 1399 
them. Biofeedback therapy has been consistently reported to be superior to 1400 
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controlled treatment modalities, including sham biofeedback, placebo pill, muscle 1401 
relaxant drugs (diazepam), and osmotic laxatives.248, 249 Improved anorectal 1402 
physiology correlated with successful outcomes, supporting a specific mechanism of 1403 
action of biofeedback that differed from psychotherapy interventions and simple 1404 
education. Biofeedback was effective in the long term and devoid of side effects, as 1405 
confirmed by a recent open-label trial with a follow-up interval extended up to 4 1406 
years.248, 249, 251, 252 In the pivotal trials, a complex protocol addressing the defecation 1407 
effort as a whole using dedicated instruments was employed248-250; this seems 1408 
relevant to the successful outcome of biofeedback therapy, as simpler protocols were 1409 
less effective than alternative treatments in FDDs.153 In addition, constipation 1410 
symptoms associated with isolated anatomical disruption of the pelvic floor seem to 1411 
benefit little from retraining.253 Factors that may predict successful outcome of 1412 
biofeedback therapy are: baseline harder stool consistency, digital manoeuvres to 1413 
facilitate defecation, shorter duration of laxative use, higher resting anal sphincter 1414 
pressure, and failure to expel a rectal balloon.70, 254 Comorbid slow colonic transit is 1415 
not a contraindication to retraining, as it has been repeatedly shown that improved 1416 
defecation effort is effective on normalizing bowel transit in the vast majority of DD 1417 
patients.79, 254 Finally, the patient’s willingness to participate, motivation and 1418 
therapist’s skill are all considered relevant to a successful outcome, although these 1419 
are generally not specifically addressed.255  1420 
 1421 
Future research/unmet needs: 1422 
Other RCTs of biofeedback for constipation due to inadequate rectal propulsion with 1423 
or without DD should be conducted. They should include both subjective and 1424 
objective outcome measures, such as structural alterations of the pelvic floor. RCTs 1425 
comparing simple bowel retraining measures to instrumented biofeedback for 1426 
constipation due to FDDs are needed. RCTs for constipation due to FDDs aimed at 1427 
standardizing biofeedback protocols for DD and inadequate rectal propulsion are 1428 
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also required, as well as RCTs comparing biofeedback with conservative care for 1429 
constipation due to structural alterations of the pelvic floor. 1430 
 1431 
Statement 56: Habit training is an effective treatment option for chronic 1432 
constipation non-responsive to standard care whenever dedicated expertise is 1433 
available 1434 
a. Level of evidence: Low 1435 
b. Recommendation: Weak 1436 
c. Level of agreement: 100 %  1437 
 1438 
Current evidence and literature:  1439 
Habit training, also called bowel retraining or pelvic floor retraining, has been 1440 
developed to address constipation as a multifactorial disorder with a particular focus 1441 
on the pelvic outlet. Habit training is generally not provided according to a 1442 
standardised protocol, and is mostly a nurse-led treatment option.256, 257 It involves 1443 
dietary advice to improve stool consistency and to maximize the gastro-colic 1444 
response in order to ease defecation.256, 257 Patients can be given basic gut anatomy 1445 
and function training to gain an appreciation of how psychological and social stresses 1446 
may influence gut functioning, as well as advice about the frequency and length of 1447 
toilet visits and posture. Simple pelvic floor exercises and abdominal muscular 1448 
coordination training to improve the pushing effort are relevant treatment 1449 
components in all protocols.256, 257 However, habit training is not like biofeedback, 1450 
where information about a physiological process is presented to enable mastering of 1451 
a disordered function.255 Some centres provide this treatment approach in all 1452 
resistant chronic constipation, regardless of aetiology.257 However, a pelvic floor 1453 
retraining protocol was prescribed as sole treatment for 22% of constipated Italian 1454 
patients consulting specialised care.248 The recently published St Mark’s experience 1455 
has shed some light on habit training given to constipated patients non-responsive to 1456 
conservative care.2587 A retrospective analysis of data from 347 mostly female 1457 
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constipated subjects (median age, 50 years) showed an improvement in symptoms 1458 
in 62.5% and in the QoL score in 40.2% of the patients at the end of treatment. 1459 
Multivariate analysis demonstrated that increasing age, the number of sessions 1460 
attended, and non-irrigation constipation were independent predictors of treatment 1461 
satisfaction.257 No side effects were reported. The same group undertook an 1462 
historical RCT comparing electromyography (EMG) on straining and rectal balloon 1463 
biofeedback to abdomino-pelvic muscular coordination training and balloon feedback 1464 
in a series of 60 adults with functional constipation unresponsive to conservative 1465 
management.259 After only two unsatisfactory sessions, patients who were judged 1466 
unable to respond were switched to the alternative treatment, thus biasing the 1467 
results. At the end of treatment, approximately 50% of patients in both groups rated 1468 
their symptoms as significantly improved. The outcome did not correlate with colon 1469 
transit time, the presence of FDD, or other functional and clinical variables.259 No 1470 
other RCTs have attempted to duplicate the results in the adult population. 1471 
In conclusion, habit training is an appealing treatment option for chronic constipation, 1472 
regardless of aetiology. It is a safe and affordable treatment option. Dedicated 1473 
expertise is essential to perform it, but costly pre-treatment testing is apparently not 1474 
required. It comprises a non-drug, non-instrumental, holistic approach that is likely to 1475 
appeal to patients with functional gastrointestinal disorders. However, it is not an 1476 
evidence-based treatment and results from RCTs are pending before consistently 1477 
endorsing it for all refractory constipation patients.260 1478 
 1479 
Future research/unmet needs: 1480 
RCTs comparing habit training to instrumented biofeedback for constipation due to 1481 
FDDs including both subjective and objective outcome measures should be 1482 
conducted. RCTs comparing habit training to laxatives and different habit training 1483 
protocols for chronic constipation are also needed, as well as RCTs comparing habit 1484 
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training with biofeedback for constipation due to structural alterations of the pelvic 1485 
floor. 1486 
 1487 
ALTERNATIVE TREATMENTS 1488 
Statement 57: Chinese herbal medicine improves bowel function in functional 1489 
constipation, but it is not known which formulation is best. 1490 
a. Level of evidence: Low 1491 
b. Recommendation: Weak 1492 
c. Level of agreement: 100 % 1493 
 1494 
Current evidence and literature:  1495 
A large proportion of patients with constipation have tried alternative remedies,261, 262 1496 
partly because of the misconception that laxatives damage the bowel in some way or 1497 
make it lazy. In addition, many patients like to think that they are treating their 1498 
constipation in a more ‘natural’ way and, therefore, food or plant extracts that are 1499 
thought to have a laxative effect are very popular. 1500 
Alternative remedies are also often used by patients with IBS, and there are more 1501 
studies for this condition than for FC.263-265 1502 
This raises the possibility of using data derived from IBS-C patients. However, the 1503 
outcome measures used in these studies on alternative treatments in IBS tend to be 1504 
more global, rather than reporting the actual effect on bowel function. Furthermore, 1505 
even in those studies that divide patients into different bowel function subtypes, the 1506 
outcomes are also usually global, rather than necessarily reporting specifically on 1507 
change in stool form or frequency. Despite these drawbacks, where there is a lack of 1508 
data with respect to the effect of alternative treatments in chronic constipation, it 1509 
seems reasonable to consider extrapolating results from studies reporting results 1510 
from IBS-C to chronic constipation.  1511 
60 
 
In contrast to most other alternative approaches to treating constipation, Chinese 1512 
herbal medicines have been the subject of more recent research in reasonably well-1513 
designed controlled trials. The results from these trials have shown consistently 1514 
encouraging results.266-271 However, the formulation of these products can vary, 1515 
making it difficult to create specific recommendations on their use. 1516 
 1517 
Future research/unmet needs: 1518 
Many of the alternative remedies for the treatment of constipation have been 1519 
available for many years, but very few have been subjected to the scrutiny of a 1520 
modern clinical trial. This situation is unlikely to change in the future, as it is doubtful 1521 
that funding for research of these established, but largely unproven approaches, will 1522 
be forthcoming.  Many of these preparations contain multiple components and it 1523 
would be useful to know whether all of the components are necessary for a clinical 1524 
effect. 1525 
 1526 
Statement 58: There is insufficient evidence to recommend acupuncture for the 1527 
treatment of functional constipation 1528 
a. Level of evidence: Very low 1529 
b. Recommendation: Weak 1530 
c. Level of agreement: 100 % 1531 
 1532 
Current evidence and literature:  1533 
Studies on acupuncture in any disorder are always criticised because of the difficulty 1534 
in finding an appropriate control group. A systematic review of IBS acupuncture 1535 
studies was inconclusive,272 and there have been too few studies on constipation in 1536 
the English literature to draw any firm conclusions.267, 273 However, a systematic 1537 
review of the Chinese literature suggests that acupuncture may be beneficial in 1538 
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constipation, although the authors commented that the studies had methodological 1539 
flaws.274 1540 
 1541 
Future research/unmet needs: 1542 
Better designed trials are necessary before a final decision can be made about the 1543 
utility of acupuncture in constipation. 1544 
 1545 
 1546 
Statement 59: There is insufficient evidence to recommend moxibustion for the 1547 
treatment of functional constipation 1548 
a. Level of evidence: Very low 1549 
b. Recommendation: Weak 1550 
c. Level of agreement: 100 % 1551 
 1552 
Current evidence and literature:  1553 
Moxibustion is a technique for applying heat to acupuncture points and is widely 1554 
used in Asian countries. A systematic review of its use in constipation published in 1555 
2010 was inconclusive and a subsequent study was negative.275, 276 1556 
 1557 
Future research/unmet needs: 1558 
Further trials are unlikely to provide enough new information to change practice. 1559 
 1560 
 1561 
Statement 60: There is insufficient evidence to recommend herbal remedies for 1562 
the treatment of functional constipation 1563 
a. Level of evidence: Very low 1564 
b. Recommendation: Weak 1565 
62 
 
c. Level of agreement: 100 % 1566 
 1567 
Current evidence and literature:  1568 
It has been suggested that Iberogast (STW 5) may be beneficial in IBS,277 but there 1569 
are no data on its use in constipation. Other studies on herbal preparations are either 1570 
conflicting, negative or of poor quality according to our understanding of medicine.261, 1571 
278-282 1572 
 1573 
Future research/unmet needs: 1574 
Better designed trials are necessary and in particular emphasis should be placed on 1575 
determining the relative contribution of the multiple constituents of these preparations 1576 
to the clinical effect. 1577 
 1578 
Statement 61: Abdominal massage may have an effect in functional 1579 
constipation, but the way it is performed needs to be standardised before it 1580 
can be recommended 1581 
a. Level of evidence: Very low 1582 
b. Recommendation: Weak 1583 
c. Level of agreement:  100 % 1584 
 1585 
Current evidence and literature:  1586 
Abdominal massage would appear to be an attractive approach to managing 1587 
constipation, as it should be a safe and cheap option in which the patient can 1588 
engage. Trials show some effect, although the methodology of the older trials is 1589 
questionable. In contrast, the more recent studies are better designed and still show 1590 
an effect.261, 283-286  1591 
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 1592 
Future research/unmet needs: 1593 
More uniform and confirmatory studies using a standardised approach should be 1594 
performed before abdominal massage can be recommended. 1595 
 1596 
Statement 62: Behavioural approaches such as psychotherapy, cognitive 1597 
behavioural therapy and hypnotherapy may improve quality of life and coping 1598 
in functional constipation, but there is no research evidence to suggest that 1599 
they directly improve bowel function in this disorder. 1600 
a. Level of evidence: Very low 1601 
b. Recommendation: Weak 1602 
c. Level of agreement: 100 % 1603 
 1604 
Current evidence and literature:  1605 
Behavioural treatments such as psychotherapy, cognitive behavioural therapy and 1606 
hypnotherapy have all been shown to be effective in IBS.287 It therefore seems 1607 
reasonable to assume that, at the very least, they might improve coping and QoL in 1608 
patients with FC. 1609 
 1610 
Future research/unmet needs: 1611 
The specific effect of behavioural treatments on constipation has not been 1612 
investigated and there are no studies on the use of any these behavioural 1613 
approaches in FC. 1614 
 1615 
Statement 63: Despite a lack of good research evidence, rectal suppositories 1616 
are frequently used to treat constipation and probably have some effect. They 1617 
are not associated with any obvious risks. 1618 
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a. Level of evidence: Low 1619 
b. Recommendation: Strong 1620 
c. Level of agreement: 100 % 1621 
 1622 
Current evidence and literature:  1623 
Glycerin or bisacodyl suppositories are frequently used as over-the-counter remedies 1624 
for FC. However, there has been no good quality research on the subject, although 1625 
studies that have been undertaken suggest an effect.163, 288 1626 
 1627 
Future research/unmet needs: 1628 
Further trials on assessing the utility of these well used remedies would be welcome. 1629 
 1630 
 1631 
Statement 64: Rectal enemas are frequently used to aid evacuation of the distal 1632 
colon and rectum, although there is no research evidence to support their use. 1633 
However, a trial of enemas is probably justified in patients in whom all other 1634 
measures have failed. They should be avoided in people at risk of fluid or 1635 
electrolyte imbalance, such as those with cardiac or renal disease. 1636 
a. Level of evidence: Low 1637 
b. Recommendation: Strong 1638 
c. Level of agreement: 100 % 1639 
 1640 
Current evidence and literature:  1641 
Enemas have been used for centuries to treat constipation, but unfortunately there 1642 
have been no studies on their use in chronic constipation. They continue to be widely 1643 
used and are available in ready-made delivery systems containing between 5 and 1644 
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150 mL of fluid. The larger volume products should be avoided in the elderly or 1645 
patients with renal or cardiac disease because of the potential for fluid overload or 1646 
electrolyte problems, especially with phosphate enemas.163, 288, 289 1647 
 1648 
Future research/unmet needs: 1649 
Further well designed trials on assessing the utility of enemas would be welcome. 1650 
 1651 
 1652 
Statement 65: Uncontrolled studies suggest that transanal irrigation improves 1653 
constipation, especially where laxatives have failed. The risk of perforation is 1654 
very low. 1655 
a. Level of evidence: Low 1656 
b. Recommendation: Weak 1657 
c. Level of agreement: 100 % 1658 
Current evidence and literature:  1659 
Transanal irrigation using commercially available kits is being increasingly used for 1660 
the management of bowel dysfunction, including FC. A systematic review and meta-1661 
analysis of the available uncontrolled studies in FC suggested a 50% response rate, 1662 
which is comparable to that obtained with pharmacological agents.290 Theoretically, 1663 
this technique could lead to perforation, but a separate study addressing this 1664 
possibility has suggested this risk is very low.291 Active or suspected diverticulitis are 1665 
contraindications and previous rectal or pelvic surgery increases the chances of 1666 
perforation. Good instruction on how to use the technique is essential.292 Colonic 1667 
irrigation using large volumes of fluid is very popular as a private service but is not 1668 
offered within healthcare systems. It is not recommended as there is no clinical or 1669 
research evidence to support its use and it is potentially dangerous. 1670 
 1671 
66 
 
Future research/unmet needs: 1672 
Controlled trials of transanal irrigation in chronic constipation are needed. 1673 
 1674 
 1675 
MODULATION OF MICROBIOTA 1676 
Statement 66. There is insufficient evidence to recommend faecal microbiota 1677 
transfer (FMT) for routine treatment of functional constipation. 1678 
a. Level of evidence: Low 1679 
b. Recommendation: Weak 1680 
c. Level of agreement: 100 % 1681 
 1682 
Current evidence and literature:  1683 
A change in the faecal microbiota composition has been described in IBS patients. 1684 
This has supported the assumption that faecal microbiota transfer (FMT) may be a 1685 
therapeutic approach, particularly in patients with diarrhoea and IBS. 1686 
Only a few well-designed clinical studies have been performed in IBS patients. 1687 
Johnsen et al.293 reported on a double-blind, randomised, placebo-controlled, 1688 
parallel-group, single-centre study in 90 patients with IBS with diarrhoea alone or 1689 
with diarrhoea and constipation as defined by the Rome III criteria. Patients were 1690 
randomly assigned (2:1) to receive either active or placebo FMT. The primary 1691 
endpoint was symptom relief of more than 75 points assessed by the IBS Severity 1692 
Scoring System (IBS-SSS) 3 months after FMT. Sixty-five percent of patients 1693 
receiving active treatment versus 43% of patients receiving the placebo showed 1694 
symptom relief 3 months after FMT (p=0.049); however, a separate analysis for the 1695 
patients who also had constipation symptoms was not performed. Halkjaer et al.294 1696 
performed a randomised, double-blind placebo-controlled trial to compare FMT 1697 
versus placebo in 52 adult patients with moderate-to-severe IBS. The FMT was given 1698 
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orally via capsules. The investigators found a significant improvement in the IBS-SSS 1699 
score in the treatment group after 3 months (p=0.012) in favour of the placebo and 1700 
not the FMT. This could indicate that the route of administration is crucial 1701 
(colonoscopy versus oral administration). As patients with oral FMT also had 1702 
persistent changes in their colonic microbiota composition, it may be concluded that 1703 
altering the gut microbiota is not sufficient to obtain clinical improvement in IBS.294 No 1704 
subgroup analysis is available for IBS-C in this study. 1705 
Few studies with a number of methodological limitations have studied FMT in chronic 1706 
constipation without IBS diagnosis. Ding et al. report an improvement in about a third 1707 
of patients after three months.295 However, patients were treated with vancomycin 1708 
prior to FMT and used 2 liters of macrogol solution for bowel lavage. No sham control 1709 
or placebo group was studied making it hard to conclude on the effectiveness of 1710 
FMT. In a randomized trial Tian and colleagues provided evidence for superiority of 1711 
FMT given by nasoduodenal tube for six consecutive days: The clinical improvement 1712 
rate (ITT) was 53.3% vs. 20.0%, P = 0.009. The observation period was 12 weeks. 1713 
The control group received no tube and no placebo transplant but only conventional 1714 
treatment consisting of education, behavioural strategies, and oral laxatives, No long-1715 
term follow up data are available and the difference between the treatments makes it 1716 
again hard to draw solid conclusions.296 Zhang and coworkers performed another 1717 
uncontrolled trial on FMT in 29 patients.297 After 6 FMTs per patient they reported 1718 
clinical remission at week 4 in 69.0% of patients. After one year 48.3% of the patients 1719 
continued to have at least three complete spontaneous bowel movements per week. 1720 
Again, the lack of a control group makes it hard to interpret these results.  1721 
 1722 
Given the uncertainties in the definitive effect of FMT for the optimal route of 1723 
administration, optimal choice of donor, optimal frequency of application, long-term 1724 
outcome, and the lack of randomized, placebo/sham controlled trials, there is 1725 
insufficient evidence to support such an approach in routine clinical practice. 1726 
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 1727 
Future research/unmet needs: 1728 
A number of different case reports and case series have been published; however, 1729 
controlled trials are sparse. In patients with constipation, well-designed trials are 1730 
lacking and should be performed. 1731 
 1732 
Statement 67. There is some limited evidence for a positive effect of probiotic 1733 
preparations on acceleration of intestinal transit time and improvements in 1734 
stool frequency in both children and adults. However, studies are generally of 1735 
high heterogeneity and the optimal species/strains are unknown. Therefore, 1736 
there is no sufficient evidence to recommend a specific probiotic 1737 
preparation/strain for the treatment of functional constipation. 1738 
a. Level of evidence: Low 1739 
b. Recommendation: Weak 1740 
c. Level of agreement: 100 % 1741 
 1742 
Current evidence and literature:  1743 
Moreira et al. found no difference in an RCT comparing an intervention group 1744 
receiving a probiotic fermented milk beverage with a control group receiving non-1745 
probiotic milk in 49 female patients with chronic constipation.298 Interestingly, the 1746 
consumption of milk resulted in an improvement in constipation symptoms, 1747 
regardless of the probiotic culture.298 In a well-designed RCT, Spiller et al. reported a 1748 
positive effect of Saccharomyces cerevisiae in patients with IBS-C.299 The study 1749 
included 379 patients who received either 1000 mg of the probiotic or placebo for 12 1750 
weeks. While there was no overall benefit of S. cerevisiae on IBS symptoms and 1751 
well-being in the total study population, a significant improvement was observed in 1752 
the IBS-C subjects with respect to abdominal pain/discomfort and bloating.299 1753 
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However, this subgroup analysis had not been planned initially. Mezzasalma et al., in 1754 
a randomised, double-blind, three-arm parallel group trial in 150 IBS-C patients who 1755 
received either a daily oral dose of two probiotic mixtures or placebo (for 60 days) 1756 
found a higher response rate in the two treatment groups.300 An increase in bowel 1757 
movement frequency, improvement in stool consistency and reduction in abdominal 1758 
bloating were reported in 70%, 60%, and 47% of patients in a study with the probiotic 1759 
preparation VSL#3, which contains 8 different bacterial strains.301  1760 
Older studies have been summarised in a 2014 meta-analysis by Ford, Quigley and 1761 
co-authors, who selected 43 RCTs.302 In their analysis, probiotics had beneficial 1762 
effects on abdominal pain, bloating, and flatulence scores in general.302 In only two 1763 
RCTs that focused on constipation, limited beneficial effects were described (mean 1764 
increase in number of stools per week = 1.49; 95% CI=1.02-1.96).303, 304 1765 
The RCTs studied different bacterial preparations for different treatment periods, with 1766 
or without PEG, with different endpoints. This obvious high heterogeneity of even the 1767 
well-designed clinical trials prevents a recommendation on a specific probiotic 1768 
preparation/strain for the treatment of FC. 1769 
 1770 
Future research/unmet needs: 1771 
RCTs need to be performed for well characterised probiotic preparations that focus 1772 
selectively either on IBS-C or FC patients. Too many post hoc subgroup analyses 1773 
have been performed that had no primary focus on constipation. Additional 1774 
microbiota analyses should be required to evaluate whether an impact on microbiota 1775 
composition is associated with symptom relief. 1776 
  1777 
SURGICAL TREATMENT 1778 
Statement 68. Surgical treatment options, both resecting and non-resecting, 1779 
might be considered for selected patients if all other conservative treatments 1780 
show no effect. 1781 
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a. Level of evidence: Moderate 1782 
b. Recommendation: Strong 1783 
c. Level of agreement: 100 % 1784 
Current evidence and literature: 1785 
Surgical interventions for chronic constipation are, and should be, rare. If all other 1786 
conservative treatment fails, there is a surgical option.305, 306 Surgical interventions 1787 
should be offered as a last resort and should be carefully considered.  1788 
Future research/unmet needs: 1789 
RCTs are lacking, there are few cases, and data in observational studies is 1790 
inconsistent. RCTs should be performed and patient selection for procedures should 1791 
be improved. 1792 
 1793 
Additional comments: 1794 
If no other treatment achieves improvement and the patient is experiencing severe 1795 
symptoms, then surgery can help to ease them as a final option. However, decision 1796 
for surgical treatment option includes acceptance of any possible surgery related 1797 
morbidity (wound infection, hernia formation, revision surgery) including even 1798 
mortality. This has to be pointed out carefully to the patient during the informed 1799 
consent discussion. 1800 
  1801 
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Statement 69:  Surgical treatment should only be offered after performing 1802 
physiological tests and only if the cause for the chronic constipation lies 1803 
within the colon and/or rectum (slow-transit constipation, evacuation disorder) 1804 
a. Level of evidence: Low 1805 
b. Recommendation: Strong 1806 
c. Level of agreement: 100 % 1807 
 1808 
Current evidence and literature: 1809 
We do not recommend performing any surgical intervention without a thorough 1810 
physiological examination.49, 307 1811 
 1812 
Future research/unmet needs: 1813 
RCTs are lacking, there are few cases, and data is inconsistent in observational 1814 
studies. RCTs should be performed and patient selection for procedures should be 1815 
improved. 1816 
 1817 
Additional comments: 1818 
Surgery is always the last resort. With this statement we want to stress that before 1819 
considering surgery, physiological testing is critical to plan for the right surgical 1820 
treatment. And of course, ONLY after all other treatment options have failed.   1821 
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Statement 70: PEC/Malone antegrade colonic enema is a non-resecting 1822 
surgical treatment to flush the large intestine orthograde through an 1823 
appendiceal stoma for highly selected patients suffering from slow transit 1824 
constipation. 1825 
a. Level of evidence: Very low 1826 
b. Recommendation: Weak 1827 
c. Level of agreement: 100 % 1828 
 1829 
Current evidence and literature 1830 
Only observational studies are available. Due to the low number of cases and lack of 1831 
RCTs, there is no recommendation for this procedure. In rare cases, the procedure is 1832 
successful. A recent study showed no improvement in QoL and the procedure also 1833 
has a high complication rate.308-311 1834 
 1835 
Future research/unmet needs 1836 
RCTs should be performed in adults. Very rarely performed procedure. 1837 
 1838 
Additional comments: 1839 
The level of recommendation is “weak” because the literature mainly focuses on 1840 
paediatric patients and the complication rate in adults is high; overall, the number of 1841 
adult patients is low. Performing RCTs in this setting is not feasible. However, it is a 1842 
procedure worth trying before performing more radical approaches such as a 1843 
definitive stoma or colectomy. Therefore, we suggest this procedure before radical 1844 
surgery. 1845 
  1846 
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Statement 71:  Continuous direct nerve stimulation (SNS/SNM) can ease 1847 
symptoms in patients suffering from chronic constipation (slow-transit 1848 
constipation and/or evacuation disorder) and is the least invasive surgical 1849 
option for patients after all conservative treatment has failed. The success rate 1850 
might be low, but the low complication rate justifies the intervention.  1851 
a. Level of evidence: Low 1852 
b. Recommendation: Weak 1853 
c. Level of agreement: 75 % 1854 
 1855 
Current evidence and literature 1856 
Three recent RCTs with n ~40-50 reported that SNS did not significantly improve 1857 
(increase) the frequency of bowel movements.312-315 However, SNS stimulates 1858 
afferent and efferent nerves which might contribute to better awareness and 1859 
consecutively ease complaints. Of all surgical therapy options SNS is the least 1860 
invasive, and despite a low success rate, SNS also has a low complication rate 1861 
which may justify its application in selected patients. Patients might choose SNS over 1862 
colectomy or definitive stoma.  1863 
Future research/unmet needs 1864 
Three recent RCTs are available. Better patient selection seems to be the main goal 1865 
for further studies. 1866 
 1867 
Additional comments: 1868 
The evidence level is too “low for a strong recommendation”, but it may be worth 1869 
trying before performing more invasive surgery.  1870 
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Statement 72: Total or segmental colectomy can be an effective treatment in 1871 
highly selected patients with normal upper GI function and slow-transit 1872 
constipation who do not respond to medical treatment and have normal 1873 
evacuatory function.  1874 
a. Level of evidence: Moderate 1875 
b. Recommendation: Strong 1876 
c. Level of agreement: 91 % 1877 
 1878 
Current evidence and literature: 1879 
In segmental colonic resection, a targeted open or laparoscopic resection of the 1880 
ineffective bowel segment is performed to improve transit time. Patients with an 1881 
isolated megasigmoid profit most from segmental colonic resection. Total colectomy 1882 
(open or laparoscopically performed) can be done by resecting or preserving the ileo-1883 
caecal  valve (ileorectal anastomosis [IRA] vs. caecorectal anastomosis [CRA]). 1884 
Complications occur in approximately 24% of cases, the most common being small 1885 
bowel obstruction. However, reported patient satisfaction is high.316 Significant 1886 
psychological disorders seem to have a negative effect on the colectomy. 1887 
 1888 
Future research/unmet needs: 1889 
In comparison to all other surgical procedures for constipation, colectomies are well 1890 
studied.  1891 
 1892 
Additional comments: 1893 
Worldwide, definitive stoma formation is probably the most frequently used surgical 1894 
option for severe constipation (due to costs and lack of physiological testing).  1895 
  1896 
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Statement 73: Surgery can be an effective treatment for patients who suffer 1897 
from an evacuation disorder due to structural causes (i.e. intussusception, 1898 
rectocele, rectal prolapse, descending perineum syndrome) proven by imaging 1899 
after failed conservative treatment. 1900 
a. Level of evidence: Moderate 1901 
b. Recommendation: Strong 1902 
c. Level of agreement: 92 % 1903 
 1904 
Current evidence and literature 1905 
The surgical method is chosen depending on the pathology. In the case of 1906 
intussusception, rectocele or prolapse, a STARR or internal Delorme procedure can 1907 
be done. Patients show a decrease in the Longo’s Obstructed defecation Score 1908 
(ODS). There is virtually no evidence in the literature to support rectocele resection 1909 
performed trans-anally, vaginally, or transperineally, with or without levatorplasty.317-1910 
319 1911 
 1912 
Future research/unmet needs: 1913 
At present, there are mostly observational studies and the evidence level is low. 1914 
 1915 
 1916 
 1917 
 1918 
  1919 
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DISCUSSION 1920 
This document presents guidelines created by the ESNM for the management of 1921 
chronic constipation. Following a careful Delphi process, 73 statements were 1922 
produced and graded according to the level of evidence and the strength of 1923 
recommendation using the GRADE method. Three algorithms were also developed 1924 
for the management of constipation. The first algorithm is for first-line management of 1925 
chronic constipation; the second for further investigation of patients with an 1926 
unsatisfactory response to first-line management; and the third is for the treatment of 1927 
constipation not caused by an evacuation disorder and which is refractory to first-line 1928 
management. In addition to recommendations for the practical management of 1929 
constipation, unmet needs were identified and future research lines proposed. 1930 
In order to develop these comprehensive guidelines that we hope will be useful 1931 
across Europe, we included experts in different fields who manage constipation, 1932 
including general practitioners, gastroenterologists, experts in neurophysiology and 1933 
motility, radiologists and surgeons, originally from eight European countries. In 1934 
general, the authors discovered only moderate or low levels of evidence for most of 1935 
the evaluated items (Table 1). Among the diagnostic studies, only the usefulness of 1936 
anorectal manometry for the comprehensive evaluation of anorectal function showed 1937 
a high level of evidence.60-62 Among the therapeutic alternatives, only treatment with 1938 
saline laxatives, especially polyethylene glycol,8, 181, 190, 191 the prokinetic drug 1939 
prucalopride,221-236 secretagogues like linaclotide and lubiprostone,55, 70, 79, 247-260, 320-324 1940 
and PAMORAs for the treatment of opioid-induced constipation 181, 238-240 showed 1941 
high levels of evidence. Despite the different backgrounds of the panel members and 1942 
the lack of studies with high levels of evidence, an excellent level of agreement 1943 
between the experts was obtained for most items, as observed in Figure 1. All but 1944 
four statements were completely agreed/agreed upon by 70% or more of the authors 1945 
(Figure 1). These four items were related to the surgical management of 1946 
constipation, with the greatest disagreement on the use of continuous direct nerve 1947 
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stimulation (SNS/SNM) for the treatment of this condition. Three newly published 1948 
RCTs have shown no benefit for SNS/SNM on stool frequency in patients with 1949 
chronic constipation,312-315 and several of the panel considered that there was no 1950 
place for this treatment modality. Nonetheless, other authors proposed a trial of 1951 
SNS/SNM before more aggressive surgical treatment is considered, mainly due to 1952 
the low rate of side effects of the technique. 1953 
 1954 
In contrast to prokinetics and secretagogues, the evidence for the efficacy of 1955 
alternative treatments and probiotics was “low” or “very low” in all cases. 1956 
Consequently, the strength of the recommendation to use these treatments is 1957 
generally “weak”. One exception was the use of suppositories and rectal enemas, 1958 
which are strongly recommended despite the low scientific evidence in the literature, 1959 
mainly because both treatments have been safely used for years worldwide.163, 280-289 1960 
For the remaining treatment modalities, the authors found at least moderate 1961 
evidence of their efficacy. However, the need for studies is great in most areas, and 1962 
the final recommendations are the result of a mixture of tradition, personal 1963 
experience and rational use of resources, as well as the available evidence. In this 1964 
regard, in some cases the guideline is a compromise between what is traditionally 1965 
used in different settings and the acceptance of different treatments in different 1966 
regions. For example, rectal enemas or anal irrigation may have varying acceptance 1967 
in different countries, and the choice of stimulant laxatives, prokinetics or 1968 
secretagogues may depend on local tradition or on local costs and access to specific 1969 
drugs. 1970 
Of note, and despite some minor differences, the present guidelines are largely 1971 
consistent with previous publications.8, 54, 55, 325, 326 The Guideline of the American 1972 
College of Gastroenterology published in 20148 also recommends bulking agents, 1973 
osmotic and stimulant laxatives, prokinetics and secretagogues, despite different 1974 
levels of evidence between the treatments, but with a weak degree of 1975 
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recommendation for non-pharmacological treatments like biofeedback therapy or 1976 
probiotics. However, these European guidelines give a strong recommendation for 1977 
biofeedback as the preferred treatment strategy for constipation in functional 1978 
defecation disorders whenever dedicated expertise is available, regardless of 1979 
abnormal bowel transit. The World Gastroenterology Organization Guideline 1980 
published in 201054 differentiated between countries with high and low technical 1981 
resources. For that reason, the colonic transit time test with radiopaque markers, 1982 
which is cheap and easy to perform, was considered a first-line option. In the present 1983 
guidelines, measurement of colonic transit time is suggested after an evacuation 1984 
disorder has been excluded, as this may delay the colonic transit time and produce 1985 
misleading results.79-81 The American Gastroenterological Association (AGA) 1986 
guidelines released 201355 considered that radiological examinations for evacuation 1987 
disorders (defecography) should be performed when anorectal manometry and the 1988 
balloon expulsion test are inconclusive. However, considering different levels of 1989 
access to motility and sophisticated radiological explorations in European countries, 1990 
we decided to put the various radiological and manometric investigations for 1991 
evacuation disorders at the same level in the algorithm.  1992 
In the present guideline, the authors reached the consensus that when an 1993 
evacuation disorder is suspected in patients non-responding to first line therapy 1994 
with bulking agents/osmotic laxatives, evaluation of an evacuation disorder with 1995 
functional studies could help to discriminate patients that could benefit from 1996 
biofeedback therapy, before a costly chronic treatment with prokinetics and/or 1997 
secretagogues is started. However, we acknowledge that this recommendation 1998 
may be controversial, and treatment with secretagogues or prokinetics at this 1999 
stage could also be considered before future studies comparing the cost-2000 
effectiveness of these strategies are available. 2001 
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An important issue on which all authors agreed was the lack of consistent 2002 
terminology in this area, resulting in considerable confusion in the medical 2003 
community. Hence, the terms functional constipation, chronic constipation, 2004 
defecation disorder, evacuation disorder, outlet obstructed evacuation, dyssynergic 2005 
defecation, etc. have been used in the literature to describe sometimes the same 2006 
and, at other times, completely different phenomena. After discussion, the authors of 2007 
these guidelines reached the consensus that the term chronic constipation be used 2008 
for all types of constipation with a duration greater than 3 months, and the terms 2009 
slow-transit constipation or normal transit constipation only when objective evidence 2010 
has been obtained from transit studies. In relation to evacuation disorders, the 2011 
generic term “evacuation disorder”, which encompasses both structural and 2012 
functional causes is used, and the specific terms “functional defecation disorder,” as 2013 
defined by the Rome IV consensus, and “structural defecation disorder” are used to 2014 
differentiate between both types of evacuation disorders. 2015 
 2016 
The aim of the guidelines is to provide a practical tool for physicians all over Europe 2017 
for the management of patients with chronic constipation. These guidelines have 2018 
addressed mainly the general adult population with chronic idiopathic constipation. 2019 
Specific groups such as those with constipation secondary to neurological disorders 2020 
or to spinal cord injury, or constipation associated with special conditions like 2021 
pregnancy have not been addressed in the present document. Likewise, the 2022 
treatment of specific complications like faecaloma, disimpaction or incontinence 2023 
secondary to constipation have not been covered here either. 2024 
 2025 
In conclusion, these ESNM guidelines for the management of chronic constipation 2026 
are presented as a practical tool for the management of adult patients with 2027 
constipation. They provide sequential algorithms for a progressive diagnostic and 2028 
management process. This starts with initial first-line assessment and management 2029 
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using general measures and bulking or saline laxatives, followed by more 2030 
comprehensive diagnostic procedures and more intensive treatment modalities in 2031 
those patients who fail to respond to first-line treatments.  2032 
81 
 
Acknowledgements, funding and disclosures:  2033 
The authors thank the ESNM Steering Committee and ESNM secretary Magdalena 2034 
Mara for their support.  2035 
There was no financial support or funding for the development of the guidelines. 2036 
Dr Serra acted as consulter/speaker for AB-biotics, Allergan, Bayer, Norgine, 2037 
Cassen-Recordati, Zespri and Reckitt Benkiser. Dr Pohl has been 2038 
consultant/speaker or received research support from Allergan, Medtronic, 2039 
Permamed and Sanofi. Dr Azpiroz has acted as a consultant or received research 2040 
funding from Danone, Clasado, Noventure and Allergan. Dr Chiarioni acted as 2041 
consultant/speaker for: Aboca, Alfa-Sigma, Allergan, Malesci, Pharmextracta, 2042 
Kyowa-Kirin, Takeda and is a member of the Anorectal Committee of the Rome 2043 
Foundation. Dr Goucerol has acted as consultant or lecturer for Kyowa Kirin, 2044 
Allergan, Sanofi, Biocodex, Mayoly-Spindler, Kyowa Kirin, Laborie, Medtronic. Dr 2045 
Hungin has served on advisory boards and received funding from Kyowa Kirin, Shire, 2046 
Allergan and Danone in the last three years. Dr Layer has acted as lecturer or 2047 
consultant for the following companies in the last three years: Abbott, Allergan, Falk, 2048 
and Nordmark. Dr Mendive has participated in training activities for general 2049 
practitioners funded by Reckitt Benckiser. Dr Rogler has consulted to Abbvie, 2050 
Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, 2051 
Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, 2052 
Vital Solutions and Zeller. Dr Scott acted as a consultant for The Laborie Group, and 2053 
received honoraria for educational/speaking activities. He has received grant funding 2054 
from Mui Scientific, Bowel & Cancer Research, and The Almond Board of California. 2055 
Dr Simrén has acted as a consultant for, or received research funding from, the 2056 
following companies: Danone Nutricia Research, Glycom, Ferring Pharmaceuticals, 2057 
AstraZeneca, Nestlé, Almirall, Allergan, Menarini, Albireo, Glycom, Shire, Tillotts, 2058 
Kyowa Kirin, Takeda, Biocodex, Alimentary Health and Norgine grants Alfa Sigma. 2059 
Dr Whorwell has acted as a consultant for, or received research funding from, the 2060 
82 
 
following companies: Allergan, Salix, ironwood Pharmaceuticals, Danone Research 2061 
and Chr. Hansen. Dr Andresen has acted as a consultant for Allergan, Bayer, 2062 
Ferring, Kyowa-Kirin, Nordmark, and Shionogi Hansen. Dr. SA Taylor has acted as 2063 
consultant to Robarts, Dr J. Pfeiffer, Dr. A. Aguilar, Dr. N. Caballero, Dr. U. Grovsi, 2064 
Dr Hasan, Dr C. Malagelada, Dr Popa, Dr. Schindler, and Dr Waha and have no 2065 
conflicts of interest to declare. 2066 
 2067 
This article is dedicated to the memory of Professor Philippe Ducrotté, who passed 2068 
away a few months before this manuscript was submitted for publication. The 2069 
authors salute his leadership, mentoring, academic contributions, and friendship. 2070 
 2071 
1. The Functional Constipation Guidelines Working Group includes: 2072 
Ariadna Aguilar and Noemi Caballero (Motility and Functional Gut Disorders 2073 
Unit, University Hospital Germans Trias i Pujol, and Department of Medicine, 2074 
Autonomous University of Barcelona, Badalona, Spain), Valeria Schindler 2075 
(Division of Gastroenterology, University Hospital Zurich, Zurich, Switzerland; 2076 
Department of Gastroenterology and Hepatology, University Hospital of 2077 
Zurich, University of Zurich, Zurich, Switzerland), Stefan-Lucian Popa (2nd 2078 
Medical Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, 2079 
Cluj-Napoca, Romania), Carolina Malagelada (Centro de Investigación 2080 
Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd; 2081 
Digestive System Research Unit, University Hospital Vall d'Hebron, 2082 
Barcelona, Spain), Viola Andresen (Department of Medicine, Israelitic 2083 
Hospital, Hamburg, Germany), James E Waha (Department of Surgery, 2084 
Division of General Surgery, Medical University of Graz, Austria), Ugo Grossi 2085 
(Neurogastroenterology Group, Centre for Neuroscience, Surgery and 2086 
Trauma, Blizard Institute, Barts and The London School of Medicine & 2087 
Dentistry, Queen Mary University London, UK), Stuart A Taylor (Centre for 2088 
83 
 
Medical Imaging, University College London, UK), Hassan SS (Division of 2089 
Diabetes, Endocrinology & Gastroenterology, University of Manchester, UK). 2090 
 2091 
 2092 
 2093 
REFERENCES 2094 
 2095 
1. Schmidt FM and Santos VL. Prevalence of constipation in the general adult 2096 
population: an integrative review. J Wound Ostomy Continence Nurs. 2014; 41: 70-6; quiz 2097 
E1-2. 2098 
2. Mugie SM, Benninga MA and Di Lorenzo C. Epidemiology of constipation in children 2099 
and adults: a systematic review. Best Pract Res Clin Gastroenterol. 2011; 25: 3-18. 2100 
3. Talley NJ, Jones M, Nuyts G and Dubois D. Risk factors for chronic constipation based 2101 
on a general practice sample. Am J Gastroenterol. 2003; 98: 1107-11. 2102 
4. Chiarelli P, Brown W and McElduff P. Constipation in Australian women: prevalence 2103 
and associated factors. Int Urogynecol J Pelvic Floor Dysfunct. 2000; 11: 71-8. 2104 
5. Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic 2105 
constipation - a European perspective: Diagnosis and treatment of chronic constipation. 2106 
Neurogastroenterology & Motility. 2011; 23: 697-710. 2107 
6. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. In: Drossman DA, Chang L, Chey 2108 
WD, Kellow J, Tack J, Whitehead WE, et al., editors. ROME IV, Functional Gastrointestinal 2109 
Disorders-Disorders of gut-brain interactions. 4th ed. Raleigh, NC: The Rome Foundation;. 2110 
2016: 967–1058. 2111 
7. Drossman DA and Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-2112 
Brain Interaction. Gastroenterology. 2016; 150: 1257-61. 2113 
8. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology 2114 
monograph on the management of irritable bowel syndrome and chronic idiopathic 2115 
constipation. Am J Gastroenterol. 2014; 109 Suppl 1: S2-26; quiz S7. 2116 
9. Peppas G, Alexiou VG, Mourtzoukou E and Falagas ME. Epidemiology of constipation 2117 
in Europe and Oceania: a systematic review. BMC Gastroenterol. 2008; 8: 5. 2118 
10. Lim YJ, Rosita J, Chieng JY and Hazizi AS. The Prevalence and Symptoms 2119 
Characteristic of Functional Constipation Using Rome III Diagnostic Criteria among Tertiary 2120 
Education Students. PLoS One. 2016; 11: e0167243. 2121 
11. Gonenne J, Esfandyari T, Camilleri M, et al. Effect of female sex hormone 2122 
supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal 2123 
women. Neurogastroenterol Motil. 2006; 18: 911-8. 2124 
12. Probert CJ, Emmett PM and Heaton KW. Intestinal transit time in the population 2125 
calculated from self made observations of defecation. J Epidemiol Community Health. 1993; 2126 
47: 331-3. 2127 
13. Chan AO, Lam KF, Hui WM, et al. Influence of positive family history on clinical 2128 
characteristics of functional constipation. Clin Gastroenterol Hepatol. 2007; 5: 197-200. 2129 
14. Ostwani W, Dolan J and Elitsur Y. Familial clustering of habitual constipation: a 2130 
prospective study in children from West Virginia. J Pediatr Gastroenterol Nutr. 2010; 50: 2131 
287-9. 2132 
84 
 
15. Bytzer P, Howell S, Leemon M, Young LJ, Jones MP and Talley NJ. Low socioeconomic 2133 
class is a risk factor for upper and lower gastrointestinal symptoms: a population based 2134 
study in 15 000 Australian adults. Gut. 2001; 49: 66-72. 2135 
16. Ludvigsson JF and Abis Study G. Epidemiological study of constipation and other 2136 
gastrointestinal symptoms in 8000 children. Acta Paediatr. 2006; 95: 573-80. 2137 
17. Allen L, Williams J, Townsend N, et al. Socioeconomic status and non-communicable 2138 
disease behavioural risk factors in low-income and lower-middle-income countries: a 2139 
systematic review. The Lancet Global Health. 2017; 5: e277-e89. 2140 
18. Lembo A and Camilleri M. Chronic constipation. N Engl J Med. 2003; 349: 1360-8. 2141 
19. Nullens S, Nelsen T, Camilleri M, et al. Regional colon transit in patients with dys-2142 
synergic defaecation or slow transit in patients with constipation. Gut. 2012; 61: 1132-9. 2143 
20. Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and 2144 
irritable bowel syndrome with constipation are similar disorders within a spectrum of 2145 
sensitization, regulated by serotonin. Gastroenterology. 2013; 145: 749-57; quiz e13-4. 2146 
21. Gladman MA, Scott SM, Chan CL, Williams NS and Lunniss PJ. Rectal hyposensitivity: 2147 
prevalence and clinical impact in patients with intractable constipation and fecal 2148 
incontinence. Dis Colon Rectum. 2003; 46: 238-46. 2149 
22. He CL, Burgart L, Wang L, et al. Decreased interstitial cell of cajal volume in patients 2150 
with slow-transit constipation. Gastroenterology. 2000; 118: 14-21. 2151 
23. Valli PV, Pohl D, Fried M, Caduff R and Bauerfeind P. Diagnostic use of endoscopic 2152 
full-thickness wall resection (eFTR)-a novel minimally invasive technique for colonic tissue 2153 
sampling in patients with severe gastrointestinal motility disorders. Neurogastroenterology 2154 
& Motility. 2018; 30: e13153. 2155 
24. Battaglia E, Serra AM, Buonafede G, et al. Long-term study on the effects of visual 2156 
biofeedback and muscle training as a therapeutic modality in pelvic floor dyssynergia and 2157 
slow-transit constipation. Dis Colon Rectum. 2004; 47: 90-5. 2158 
25. Bassotti G, Chiarioni G, Germani U, Battaglia E, Vantini I and Morelli A. Endoluminal 2159 
instillation of bisacodyl in patients with severe (slow transit type) constipation is useful to 2160 
test residual colonic propulsive activity. Digestion. 1999; 60: 69-73. 2161 
26. Bassotti G, Morelli A and Whitehead WE. Abnormal rectosigmoid myoelectric 2162 
response to eating in patients with severe idiopathic constipation (slow-transit type). Dis 2163 
Colon Rectum. 1992; 35: 753-6. 2164 
27. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ and Muller-2165 
Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999; 45: ii43-ii7. 2166 
28. Xin HW, Fang XC, Zhu LM, et al. Diagnosis of functional constipation: Agreement 2167 
between Rome III and Rome II criteria and evaluation for the practicality: FC diagnosis by 2168 
Rome III and II criteria. Journal of Digestive Diseases. 2014; 15: 314-20. 2169 
29. Cook IJ, Talley NJ, Benninga MA, Rao SS and Scott SM. Chronic constipation: 2170 
overview and challenges. Neurogastroenterology and motility : the official journal of the 2171 
European Gastrointestinal Motility Society. 2009; 21 Suppl 2: 1-8. 2172 
30. Sood R and Ford AC. Rome IV criteria for FGIDs — an improvement or more of the 2173 
same?: Diagnosis. Nature Reviews Gastroenterology & Hepatology. 2016; 13: 501-2. 2174 
31. Johanson JF and Kralstein J. Chronic constipation: a survey of the patient 2175 
perspective: PATIENT PERSPECTIVE ON CONSTIPATION. Alimentary Pharmacology & 2176 
Therapeutics. 2007; 25: 599-608. 2177 
32. Lewis SJ and Heaton KW. Stool Form Scale as a Useful Guide to Intestinal Transit 2178 
Time. Scand J Gastroentero. 1997; 32: 920-4. 2179 
33. Storr M and Storr M. Chronic constipation: current management and challenges. 2180 
Can J Gastroenterol. 2011; 25 Suppl B: 5B-6B. 2181 
34. McCallum IJD, Ong S and Mercer-Jones M. Chronic constipation in adults. BMJ. 2009; 2182 
338: b831-b. 2183 
85 
 
35. Basilisco G and Coletta M. Chronic constipation: A critical review. Digestive and Liver 2184 
Disease. 2013; 45: 886-93. 2185 
36. Shin JE, Jung H-K, Lee TH, et al. Guidelines for the Diagnosis and Treatment of 2186 
Chronic Functional Constipation in Korea, 2015 Revised Edition. Journal of 2187 
neurogastroenterology and motility. 2016; 22: 383-411. 2188 
37. Schmulson MJ and Drossman DA. What Is New in Rome IV. Journal of 2189 
neurogastroenterology and motility. 2017; 23: 151-63. 2190 
38. Suares NC and Ford AC. Prevalence of and Risk Factors for, Chronic Idiopathic 2191 
Constipation in the Community: Systematic Review and Meta-analysis. The American Journal 2192 
of Gastroenterology. 2011; 106: 1582-91. 2193 
39. Palsson OS, Whitehead WE, van Tilburg MAL, et al. Development and Validation of 2194 
the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology. 2016; 150: 1481-91. 2195 
40. Bouchoucha M, Devroede G, Mary F, Bon C, Bejou B and Benamouzig R. Painful or 2196 
Mild-Pain Constipation? A Clinically Useful Alternative to Classification as Irritable Bowel 2197 
Syndrome with Constipation Versus Functional Constipation. Digestive Diseases and 2198 
Sciences. 2018; 63: 1763-73. 2199 
41. Chandar A. Diagnosis and treatment of irritable bowel syndrome with predominant 2200 
constipation in the primary-care setting: focus on linaclotide. International Journal of 2201 
General Medicine. 2017; Volume 10: 385-93. 2202 
42. Bellini M. Irritable bowel syndrome and chronic constipation: Fact and fiction. World 2203 
Journal of Gastroenterology. 2015; 21: 11362. 2204 
43. Andresen V, Banerji V, Hall G, Lass A and Emmanuel AV. The patient burden of 2205 
opioid-induced constipation: New insights from a large, multinational survey in five 2206 
European countries. United European Gastroenterology Journal. 2018; 6: 1254-66. 2207 
44. Farmer AD, Holt CB, Downes TJ, Ruggeri E, Del Vecchio S and De Giorgio R. 2208 
Pathophysiology, diagnosis, and management of opioid-induced constipation. The Lancet 2209 
Gastroenterology & Hepatology. 2018; 3: 203-12. 2210 
45. Gupta A. Improving the recognition and diagnosis of opioid-induced constipation in 2211 
clinical practice. J Fam Pract. 2015; 64. 2212 
46. Rao SS, Ozturk R and Laine L. Clinical utility of diagnostic tests for constipation in 2213 
adults: a systematic review. Am J Gastroenterol. 2005; 100: 1605-15. 2214 
47. Saad RJ, Rao SS, Koch KL, et al. Do stool form and frequency correlate with whole-2215 
gut and colonic transit? Results from a multicenter study in constipated individuals and 2216 
healthy controls. Am J Gastroenterol. 2010; 105: 403-11. 2217 
48. Bharucha AE, Pemberton JH and Locke GR. American Gastroenterological 2218 
Association Technical Review on Constipation. Gastroenterology. 2013; 144: 218-38. 2219 
49. Bove A. Consensus statement AIGO/SICCR: Diagnosis and treatment of chronic 2220 
constipation and obstructed defecation (part I: Diagnosis). World Journal of 2221 
Gastroenterology. 2012; 18: 1555. 2222 
50. Talley NJ. How to Do and Interpret a Rectal Examination in Gastroenterology. The 2223 
American Journal of Gastroenterology. 2008; 103: 820-2. 2224 
51. Soh JS, Lee HJ, Jung KW, et al. The Diagnostic Value of a Digital Rectal Examination 2225 
Compared With High-Resolution Anorectal Manometry in Patients With Chronic 2226 
Constipation and Fecal Incontinence. The American Journal of Gastroenterology. 2015; 110: 2227 
1197-204. 2228 
52. Rao SSC. Constipation: Evaluation and Treatment of Colonic and Anorectal Motility 2229 
Disorders. Gastroenterology Clinics of North America. 2007; 36: 687-711. 2230 
53. Lam TJ and Felt-Bersma RJF. Clinical examination remains more important than 2231 
anorectal function tests to identify treatable conditions in women with constipation. Int 2232 
Urogynecol J. 2013; 24: 67-72. 2233 
86 
 
54. Lindberg G, Hamid SS, Malfertheiner P, et al. World Gastroenterology Organisation 2234 
global guideline: Constipation--a global perspective. J Clin Gastroenterol. 2011; 45: 483-7. 2235 
55. Bharucha AE, Pemberton JH and Locke GR, 3rd. American Gastroenterological 2236 
Association technical review on constipation. Gastroenterology. 2013; 144: 218-38. 2237 
56. Videlock EJ, Lembo A and Cremonini F. Diagnostic testing for dyssynergic defecation 2238 
in chronic constipation: meta-analysis. Neurogastroenterology and motility : the official 2239 
journal of the European Gastrointestinal Motility Society. 2013; 25: 509-20. 2240 
57. Rao SS, Bharucha AE, Chiarioni G, et al. Functional Anorectal Disorders. 2241 
Gastroenterology. 2016. 2242 
58. Heinrich H, Fruehauf H, Sauter M, et al. The effect of standard compared to 2243 
enhanced instruction and verbal feedback on anorectal manometry measurements. 2244 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 2245 
Motility Society. 2013; 25: 230-7, e163. 2246 
59. Grossi U, Carrington EV, Bharucha AE, Horrocks EJ, Scott SM and Knowles CH. 2247 
Diagnostic accuracy study of anorectal manometry for diagnosis of dyssynergic defecation. 2248 
Gut. 2016; 65: 447-55. 2249 
60. Rao SS and Patcharatrakul T. Diagnosis and Treatment of Dyssynergic Defecation. 2250 
Journal of neurogastroenterology and motility. 2016; 22: 423-35. 2251 
61. Salvador F, Mego M, Sánchez-Montalvá A, et al. Assessment of rectocolonic 2252 
morphology and function in patients with Chagas disease in Barcelona (Spain). Am J Trop 2253 
Med Hyg. 2015; 92: 898-902. 2254 
62. Azpiroz F, Enck P and Whitehead WE. Anorectal functional testing: review of 2255 
collective experience. Am J Gastroenterol. 2002; 97: 232-40. 2256 
63. Carrington EV, Heinrich H, Knowles CH, et al. Methods of anorectal manometry vary 2257 
widely in clinical practice: Results from an international survey. Neurogastroenterology and 2258 
motility : the official journal of the European Gastrointestinal Motility Society. 2017. 2259 
64. Carrington EV, Grossi U, Knowles CH and Scott SM. Normal values for high-2260 
resolution anorectal manometry: a time for consensus and collaboration. 2261 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 2262 
Motility Society. 2014; 26: 1356-7. 2263 
65. Rasijeff AMP, Withers M, Burke JM, Jackson W and Scott SM. High-resolution 2264 
anorectal manometry: A comparison of solid-state and water-perfused catheters. 2265 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 2266 
Motility Society. 2017; 29. 2267 
66. Kang HR, Lee JE, Lee JS, et al. Comparison of High-resolution Anorectal Manometry 2268 
With Water-perfused Anorectal Manometry. Journal of neurogastroenterology and motility. 2269 
2015; 21: 126-32. 2270 
67. Vitton V, Ben Hadj Amor W, Baumstarck K, Grimaud JC and Bouvier M. Water-2271 
perfused manometry vs three-dimensional high-resolution manometry: a comparative study 2272 
on a large patient population with anorectal disorders. Colorectal Dis. 2013; 15: e726-31. 2273 
68. Jones MP, Post J and Crowell MD. High-resolution manometry in the evaluation of 2274 
anorectal disorders: a simultaneous comparison with water-perfused manometry. Am J 2275 
Gastroenterol. 2007; 102: 850-5. 2276 
69. Caetano AC, Santa-Cruz A and Rolanda C. Digital Rectal Examination and Balloon 2277 
Expulsion Test in the Study of Defecatory Disorders: Are They Suitable as Screening or 2278 
Excluding Tests? Can J Gastroenterol Hepatol. 2016; 2016: 8654314. 2279 
70. Shim LS, Jones M, Prott GM, Morris LI, Kellow JE and Malcolm A. Predictors of 2280 
outcome of anorectal biofeedback therapy in patients with constipation. Aliment Pharmacol 2281 
Ther. 2011; 33: 1245-51. 2282 
87 
 
71. Minguez M, Herreros B, Sanchiz V, et al. Predictive value of the balloon expulsion 2283 
test for excluding the diagnosis of pelvic floor dyssynergia in constipation. Gastroenterology. 2284 
2004; 126: 57-62. 2285 
72. Lee J, Hong KS, Kim JS and Jung HC. Balloon Expulsion Test Does Not Seem to Be 2286 
Useful for Screening or Exclusion of Dyssynergic Defecation as a Single Test. Journal of 2287 
neurogastroenterology and motility. 2017; 23: 446-52. 2288 
73. Palit S, Thin N, Knowles CH, Lunniss PJ, Bharucha AE and Scott SM. Diagnostic 2289 
disagreement between tests of evacuatory function: a prospective study of 100 constipated 2290 
patients. Neurogastroenterology and motility : the official journal of the European 2291 
Gastrointestinal Motility Society. 2016; 28: 1589-98. 2292 
74. Carrington EV, Scott SM, Bharucha A, et al. Expert consensus document: Advances in 2293 
the evaluation of anorectal function. Nat Rev Gastroenterol Hepatol. 2018; 15: 309-23. 2294 
75. Voskuijl WP, van Ginkel R, Benninga MA, Hart GA, Taminiau JA and Boeckxstaens GE. 2295 
New insight into rectal function in pediatric defecation disorders: disturbed rectal 2296 
compliance is an essential mechanism in pediatric constipation. The Journal of pediatrics. 2297 
2006; 148: 62-7. 2298 
76. van den Berg MM, Voskuijl WP, Boeckxstaens GE and Benninga MA. Rectal 2299 
compliance and rectal sensation in constipated adolescents, recovered adolescents and 2300 
healthy volunteers. Gut. 2008; 57: 599-603. 2301 
77. van den Berg MM, Bongers ME, Voskuijl WP and Benninga MA. No role for increased 2302 
rectal compliance in pediatric functional constipation. Gastroenterology. 2009; 137: 1963-9. 2303 
78. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical 2304 
practice: position paper of the American and European Neurogastroenterology and Motility 2305 
Societies. Neurogastroenterology and motility : the official journal of the European 2306 
Gastrointestinal Motility Society. 2011; 23: 8-23. 2307 
79. Chiarioni G, Salandini L and Whitehead WE. Biofeedback benefits only patients with 2308 
outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology. 2309 
2005; 129: 86-97. 2310 
80. Shin A, Camilleri M, Nadeau A, et al. Interpretation of overall colonic transit in 2311 
defecation disorders in males and females. Neurogastroenterology and motility : the official 2312 
journal of the European Gastrointestinal Motility Society. 2013; 25: 502-8. 2313 
81. Quitadamo P, Thapar N, Staiano A, et al. Effect of Bowel Cleansing on Colonic Transit 2314 
Time Measurement in Children with Chronic Constipation. The Journal of pediatrics. 2015; 2315 
167: 1440-2.e1. 2316 
82. Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J and Simrén M. 2317 
Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol. 2012; 107: 754-2318 
60. 2319 
83. Ekengren K and Snellman B. Roentgen appearances in mechanical rectal 2320 
constipation. Acta radiol. 1953; 40: 447-56. 2321 
84. Skomorowska E, Henrichsen S, Christiansen J and Hegedus V. Videodefaecography 2322 
combined with measurement of the anorectal angle and of perineal descent. Acta Radiol. 2323 
1987; 28: 559-62. 2324 
85. Agachan F, Chen T, Pfeifer J, Reissman P and Wexner SD. A constipation scoring 2325 
system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 2326 
1996; 39: 681-5. 2327 
86. Poon FW, Lauder JC and Finlay IG. Technical report: evacuating proctography--a 2328 
simplified technique. Clin Radiol. 1991; 44: 113-6. 2329 
87. Hainsworth AJ, Solanki D, Hamad A, Morris SJ, Schizas AM and Williams AB. 2330 
Integrated total pelvic floor ultrasound in pelvic floor defaecatory dysfunction. Colorectal 2331 
Dis. 2017; 19: O54-O65. 2332 
88 
 
88. Thompson JR, Chen AH, Pettit PD and Bridges MD. Incidence of occult rectal 2333 
prolapse in patients with clinical rectoceles and defecatory dysfunction. Am J Obstet 2334 
Gynecol. 2002; 187: 1494-9; discussion 9-500. 2335 
89. Marti, Roche and Deleaval. Rectoceles: value of videodefaecography in selection of 2336 
treatment policy. Colorectal Dis. 1999; 1: 324-9. 2337 
90. Faucheron JL and Dubreuil A. Rectal akinesia as a new cause of impaired defecation. 2338 
Dis Colon Rectum. 2000; 43: 1545-9. 2339 
91. Bartolo DC, Bartram CI, Ekberg O, et al. Symposium. Proctography. International 2340 
journal of colorectal disease. 1988; 3: 67-89. 2341 
92. Palit S, Bhan C, Lunniss PJ, et al. Evacuation proctography: a reappraisal of normal 2342 
variability. Colorectal Dis. 2014; 16: 538-46. 2343 
93. Shorvon PJ, McHugh S, Diamant NE, Somers S and Stevenson GW. Defecography in 2344 
normal volunteers: results and implications. Gut. 1989; 30: 1737-49. 2345 
94. Goh V, Halligan S, Kaplan G, Healy JC and Bartram CI. Dynamic MR imaging of the 2346 
pelvic floor in asymptomatic subjects. AJR Am J Roentgenol. 2000; 174: 661-6. 2347 
95. Tirumanisetty P, Prichard D, Fletcher JG, Chakraborty S, Zinsmeister AR and 2348 
Bharucha AE. Normal values for assessment of anal sphincter morphology, anorectal motion, 2349 
and pelvic organ prolapse with MRI in healthy women. Neurogastroenterology and motility : 2350 
the official journal of the European Gastrointestinal Motility Society. 2018. 2351 
96. Grossi U, Di Tanna GL, Heinrich H, Taylor SA, Knowles CH and Scott SM. Systematic 2352 
review with meta-analysis: defecography should be a first-line diagnostic modality in 2353 
patients with refractory constipation. Aliment Pharmacol Ther. 2018; 48: 1186-201. 2354 
97. Felt-Bersma RJ, Luth WJ, Janssen JJ and Meuwissen SG. Defecography in patients 2355 
with anorectal disorders. Which findings are clinically relevant? Dis Colon Rectum. 1990; 33: 2356 
277-84. 2357 
98. Renzi A, Izzo D, Di Sarno G, et al. Cinedefecographic findings in patients with 2358 
obstructed defecation sindrome. A study in 420 cases. Minerva Chir. 2006; 61: 493-9. 2359 
99. Klauser AG, Ting KH, Mangel E, Eibl-Eibesfeldt B and Muller-Lissner SA. Interobserver 2360 
agreement in defecography. Dis Colon Rectum. 1994; 37: 1310-6. 2361 
100. Dvorkin LS, Knowles CH, Scott SM, Williams NS and Lunniss PJ. Rectal 2362 
intussusception: characterization of symptomatology. Dis Colon Rectum. 2005; 48: 824-31. 2363 
101. Ribas Y, Saldana E, Marti-Rague J and Clave P. Prevalence and pathophysiology of 2364 
functional constipation among women in Catalonia, Spain. Dis Colon Rectum. 2011; 54: 2365 
1560-9. 2366 
102. Spazzafumo LP, V. Rectal constipation and clinical decision-making: multiple 2367 
correspondence analysis of defecographic findings. Tech Coloproctol. 1999; 3: 117-21. 2368 
103. Murad-Regadas S, Peterson TV, Pinto RA, Regadas FS, Sands DR and Wexner SD. 2369 
Defecographic pelvic floor abnormalities in constipated patients: does mode of delivery 2370 
matter? Tech Coloproctol. 2009; 13: 279-83. 2371 
104. Baek HN, Hwang YH and Jung YH. Clinical Significance of Perineal Descent in Pelvic 2372 
Outlet Obstruction Diagnosed by using Defecography. J Korean Soc Coloproctol. 2010; 26: 2373 
395-401. 2374 
105. Vitton V, Vignally P, Barthet M, et al. Dynamic anal endosonography and MRI 2375 
defecography in diagnosis of pelvic floor disorders: comparison with conventional 2376 
defecography. Dis Colon Rectum. 2011; 54: 1398-404. 2377 
106. Piloni V, Tosi P and Vernelli M. MR-defecography in obstructed defecation syndrome 2378 
(ODS): technique, diagnostic criteria and grading. Tech Coloproctol. 2013; 17: 501-10. 2379 
107. Hassan HH, Elnekiedy AM, Elshazly WG and Naguib NN. Modified MR defecography 2380 
without rectal filling in obstructed defecation syndrome: Initial experience. Eur J Radiol. 2381 
2016; 85: 1673-81. 2382 
89 
 
108. Martin-Martin GP, Garcia-Armengol J, Roig-Vila JV, et al. Magnetic resonance 2383 
defecography versus videodefecography in the study of obstructed defecation syndrome: Is 2384 
videodefecography still the test of choice after 50 years? Tech Coloproctol. 2017; 21: 795-2385 
802. 2386 
109. Poncelet E, Rock A, Quinton JF, et al. Dynamic MR defecography of the posterior 2387 
compartment: Comparison with conventional X-ray defecography. Diagn Interv Imaging. 2388 
2017; 98: 327-32. 2389 
110. Siproudhis L, Ropert A, Vilotte J, et al. How accurate is clinical examination in 2390 
diagnosing and quantifying pelvirectal disorders? A prospective study in a group of 50 2391 
patients complaining of defecatory difficulties. Dis Colon Rectum. 1993; 36: 430-8. 2392 
111. Savoye-Collet C, Savoye G, Koning E, Leroi AM and Dacher JN. Defecography in 2393 
symptomatic older women living at home. Age Ageing. 2003; 32: 347-50. 2394 
112. Nielsen MB, Buron B, Christiansen J and Hegedus V. Defecographic findings in 2395 
patients with anal incontinence and constipation and their relation to rectal emptying. Dis 2396 
Colon Rectum. 1993; 36: 806-9. 2397 
113. Kashyap AS, Kohli DR, Raizon A and Olden KW. A prospective study evaluating 2398 
emotional disturbance in subjects undergoing defecating proctography. World J 2399 
Gastroenterol. 2013; 19: 3990-5. 2400 
114. Barthet M, Portier F, Heyries L, et al. Dynamic anal endosonography may challenge 2401 
defecography for assessing dynamic anorectal disorders: results of a prospective pilot study. 2402 
Endoscopy. 2000; 32: 300-5. 2403 
115. Regadas FS, Haas EM, Abbas MA, et al. Prospective multicenter trial comparing 2404 
echodefecography with defecography in the assessment of anorectal dysfunction in patients 2405 
with obstructed defecation. Dis Colon Rectum. 2011; 54: 686-92. 2406 
116. Martellucci J and Naldini G. Clinical relevance of transperineal ultrasound compared 2407 
with evacuation proctography for the evaluation of patients with obstructed defaecation. 2408 
Colorectal Dis. 2011; 13: 1167-72. 2409 
117. Viscardi A, Ratto C and Parello A. Dynamic transperineal ultrasound in the workup of 2410 
men with obstructed defecation: a pilot study. Dis Colon Rectum. 2012; 55: 976-82. 2411 
118. Mahieu P, Pringot J and Bodart P. Defecography: I. Description of a new procedure 2412 
and results in normal patients. Gastrointestinal radiology. 1984; 9: 247-51. 2413 
119. Mahieu P, Pringot J and Bodart P. Defecography: II. Contribution to the diagnosis of 2414 
defecation disorders. Gastrointestinal radiology. 1984; 9: 253-61. 2415 
120. Lee HH, Chen SH, Chen DF and Huang CS. Defecographic evaluation of patients with 2416 
defecation difficulties. Journal of the Formosan Medical Association = Taiwan yi zhi. 1994; 2417 
93: 944-9. 2418 
121. Karlbom U, Pahlman L, Nilsson S and Graf W. Relationships between Defecographic 2419 
Findings, Rectal Emptying, and Colonic Transit-Time in Constipated Patients. Gut. 1995; 36: 2420 
907-12. 2421 
122. Glia A, Lindberg G, Nilsson LH, Mihocsa L and Akerlund JE. Constipation assessed on 2422 
the basis of colorectal physiology. Scand J Gastroentero. 1998; 33: 1273-9. 2423 
123. Stojkovic SG, Ireland IW, Holmfield JH, Sagar PM and Finan PJ. Inter-observer 2424 
variability in the reporting of dynamic evacuation proctography. Colorectal Dis. 2000; 2: 355-2425 
8. 2426 
124. Brusciano L, Limongelli P, del Genio G, et al. Clinical and instrumental parameters in 2427 
patients with constipation and incontinence: their potential implications in the functional 2428 
aspects of these disorders. International journal of colorectal disease. 2009; 24: 961-7. 2429 
125. Soares FA, Regadas FS, Murad-Regadas SM, et al. Role of age, bowel function and 2430 
parity on anorectocele pathogenesis according to cinedefecography and anal manometry 2431 
evaluation. Colorectal Dis. 2009; 11: 947-50. 2432 
90 
 
126. Morandi C, Martellucci J, Talento P and Carriero A. Role of enterocele in the 2433 
obstructed defecation syndrome (ODS): a new radiological point of view. Colorectal Disease. 2434 
2010; 12: 810-6. 2435 
127. Bartolo DC, Roe AM, Virjee J, Mortensen NJ and Locke-Edmunds JC. An analysis of 2436 
rectal morphology in obstructed defaecation. International journal of colorectal disease. 2437 
1988; 3: 17-22. 2438 
128. Schouten WR, Briel JW, Auwerda JJ, et al. Anismus: fact or fiction? Dis Colon Rectum. 2439 
1997; 40: 1033-41. 2440 
129. Dailianas A, Skandalis N, Rimikis MN, Koutsomanis D, Kardasi M and Archimandritis 2441 
A. Pelvic floor study in patients with obstructive defecation: influence of biofeedback. J Clin 2442 
Gastroenterol. 2000; 30: 176-80. 2443 
130. Gosselink MJ, Hop WC and Schouten WR. Rectal compliance in females with 2444 
obstructed defecation. Dis Colon Rectum. 2001; 44: 971-7. 2445 
131. Martin-Martin GP, Garcia-Armengol J, Roig-Vila JV, et al. Magnetic resonance 2446 
defecography versus videodefecography in the study of obstructed defecation syndrome: Is 2447 
videodefecography still the test of choice after 50 years? Techniques in coloproctology. 2448 
2017. 2449 
132. Halligan S and Bartram CI. Is digitation associated with proctographic abnormality? 2450 
International journal of colorectal disease. 1996; 11: 167-71. 2451 
133. Spazzafumo L and Piloni V. Rectal constipation and clinical decision-making: multiple 2452 
correspondence analysis of defecographic findings. . Tech Coloproctol. 1999; 3: 117–21. 2453 
134. Faucheron JL and Dubreuil A. Rectal akinesia as a new cause of impaired defecation. 2454 
Dis Colon Rectum. 2000; 43: 1545-9. 2455 
135. Bordeianou L, Savitt L and Dursun A. Measurements of Pelvic Floor Dyssynergia: 2456 
Which Test Result Matters? Diseases of the Colon & Rectum. 2011; 54: 60-5. 2457 
136. Andrade LC, Correia H, Semedo LC, Ilharco J and Caseiro-Alves F. Conventional 2458 
videodefecography: Pathologic findings according to gender and age. Eur J Radiol Open. 2459 
2014; 1: 1-5. 2460 
137. Ger GC, Wexner SD, Jorge JM and Salanga VD. Anorectal manometry in the diagnosis 2461 
of paradoxical puborectalis syndrome. Dis Colon Rectum. 1993; 36: 816-25. 2462 
138. Kassis NC, Wo JM, James-Stevenson TN, Maglinte DDT, Heit MH and Hale DS. 2463 
Balloon expulsion testing for the diagnosis of dyssynergic defecation in women with chronic 2464 
constipation. Int Urogynecol J. 2015; 26: 1385-90. 2465 
139. Zafar A, Seretis C, Feretis M, et al. Comparative study of magnetic resonance 2466 
defaecography and evacuation proctography in the evaluation of obstructed defaecation. 2467 
Colorectal Disease. 2017; 19: O204-O9. 2468 
140. Poncelet E, Rock A, Quinton JF, et al. Dynamic MR defecography of the posterior 2469 
compartment: Comparison with conventional X-ray defecography. Diagn Interv Imaging. 2470 
2017; 98: 327-32. 2471 
141. Karlbom U, Nilsson S, Pahlman L and Graf W. Defecographic study of rectal 2472 
evacuation in constipated patients and control subjects. Radiology. 1999; 210: 103-8. 2473 
142. Viscardi A, Ratto C and Parello A. Dynamic Transperineal Ultrasound in the Workup 2474 
of Men With Obstructed Defecation: A Pilot Study. Dis Colon Rectum. 2012; 55: 976-82. 2475 
143. Yeh CY, Pikarsky A, Wexner SD, et al. Electromyographic findings of paradoxical 2476 
puborectalis contraction correlate poorly with cinedefecography. Techniques in 2477 
coloproctology. 2003; 7: 77-81. 2478 
144. Pilkington SA, Nugent KP, Brenner J, et al. Barium proctography vs magnetic 2479 
resonance proctography for pelvic floor disorders: a comparative study. Colorectal Disease. 2480 
2012; 14: 1224-30. 2481 
91 
 
145. Alves-Ferreira PC, Gurland B, Zutshi M and Hull T. Perineal descent does not imply a 2482 
more severe clinical disorder. Colorectal disease : the official journal of the Association of 2483 
Coloproctology of Great Britain and Ireland. 2012; 14: 1372-9. 2484 
146. Kashyap AS, Kohli DR, Raizon A and Olden KW. A prospective study evaluating 2485 
emotional disturbance in subjects undergoing defecating proctography. World journal of 2486 
gastroenterology. 2013; 19: 3990-5. 2487 
147. Heinrich H, Sauter M, Fox M, et al. Assessment of Obstructive Defecation by High-2488 
Resolution Anorectal Manometry Compared With Magnetic Resonance Defecography. 2489 
Clinical gastroenterology and hepatology : the official clinical practice journal of the 2490 
American Gastroenterological Association. 2015; 13: 1310-7.e1. 2491 
148. Palit S, Thin N, Knowles CH, Lunniss PJ, Bharucha AE and Scott SM. Diagnostic 2492 
disagreement between tests of evacuatory function: a prospective study of 100 constipated 2493 
patients. Neurogastroenterology and motility : the official journal of the European 2494 
Gastrointestinal Motility Society. 2016; 28: 1589-98. 2495 
149. Seong M-K and Kim T-W. Significance of defecographic parameters in diagnosing 2496 
pelvic floor dyssynergia. J Korean Surg Soc. 2013; 84: 225-30. 2497 
150. Boccasanta P, Venturi M, Spennacchio M, Buonaguidi A, Airoldi A and Roviaro G. 2498 
Prospective clinical and functional results of combined rectal and urogynecologic surgery in 2499 
complex pelvic floor disorders. Am J Surg. 2010; 199: 144-53. 2500 
151. Madbouly KM, Abbas KS and Hussein AM. Disappointing Long-Term Outcomes After 2501 
Stapled Transanal Rectal Resection for Obstructed Defecation. World J Surg. 2010; 34: 2191-2502 
6. 2503 
152. Boenicke L, Jayne DG, Kim M, et al. What happens in stapled transanal rectum 2504 
resection? Dis Colon Rectum. 2011; 54: 593-600. 2505 
153. Faried M, El Nakeeb A, Youssef M, Omar W and El Monem HA. Comparative Study 2506 
between Surgical and Non-surgical Treatment of Anismus in Patients with Symptoms of 2507 
Obstructed Defecation: A Prospective Randomized Study. J Gastrointest Surg. 2010; 14: 2508 
1235-43. 2509 
154. Pilkington SA, Nugent KP, Brenner J, et al. Barium proctography vs magnetic 2510 
resonance proctography for pelvic floor disorders: a comparative study. Colorectal Dis. 2012; 2511 
14: 1224-30. 2512 
155. Zafar A, Seretis C, Feretis M, et al. Comparative study of magnetic resonance 2513 
defaecography and evacuation proctography in the evaluation of obstructed defaecation. 2514 
Colorectal Dis. 2017; 19: O204-O9. 2515 
156. Huang R, Ho S-Y, Lo W-S and Lam T-H. Physical Activity and Constipation in Hong 2516 
Kong Adolescents. PLoS ONE. 2014; 9: e90193. 2517 
157. Ayaz S and Hisar F. The efficacy of education programme for preventing constipation 2518 
in women: Education programme for constipation. International Journal of Nursing Practice. 2519 
2014; 20: 275-82. 2520 
158. Coenen C, Wegener M, Wedmann B, Schmidt G and Hoffmann S. Does physical 2521 
exercise influence bowel transit time in healthy young men? Am J Gastroenterol. 1992; 87: 2522 
292-5. 2523 
159. Meshkinpour H, Selod S, Movahedi H, Nami N, James N and Wilson A. Effects of 2524 
regular exercise in management of chronic idiopathic constipation. Dig Dis Sci. 1998; 43: 2525 
2379-83. 2526 
160. Robertson G, Meshkinpour H, Vandenberg K, James N, Cohen A and Wilson A. 2527 
Effects of exercise on total and segmental colon transit. J Clin Gastroenterol. 1993; 16: 300-2528 
3. 2529 
161. De Schryver AM, Keulemans YC, Peters HP, et al. Effects of regular physical activity 2530 
on defecation pattern in middle-aged patients complaining of chronic constipation. Scand J 2531 
Gastroenterol. 2005; 40: 422-9. 2532 
92 
 
162. Leung L, Riutta T, Kotecha J and Rosser W. Chronic Constipation: An Evidence-Based 2533 
Review. The Journal of the American Board of Family Medicine. 2011; 24: 436-51. 2534 
163. Mueller-Lissner SA and Wald A. Constipation in adults. BMJ Clin Evid. 2010; 2010. 2535 
164. Liu LW. Chronic constipation: current treatment options. Can J Gastroenterol. 2011; 2536 
25 Suppl B: 22B-8B. 2537 
165. American College of Gastroenterology Chronic Constipation Task F. An Evidence-2538 
Based Approach to the Management of Chronic Constipation in North America. The 2539 
American Journal of Gastroenterology. 2005; 100: S1-S4. 2540 
166. Lindeman RD, Romero LJ, Liang HC, Baumgartner RN, Koehler KM and Garry PJ. Do 2541 
elderly persons need to be encouraged to drink more fluids? J Gerontol A Biol Sci Med Sci. 2542 
2000; 55: M361-5. 2543 
167. Dukas L, Willett WC and Giovannucci EL. Association between physical activity, fiber 2544 
intake, and other lifestyle variables and constipation in a study of women. Am J 2545 
Gastroenterol. 2003; 98: 1790-6. 2546 
168. Nour-Eldein H, Salama HM, Abdulmajeed AA and Heissam KS. The effect of lifestyle 2547 
modification on severity of constipation and quality of life of elders in nursing homes at 2548 
Ismailia city, Egypt. J Family Community Med. 2014; 21: 100-6. 2549 
169. Suares NC and Ford AC. Systematic review: the effects of fibre in the management of 2550 
chronic idiopathic constipation: Systematic review: effect of fibre in constipation. Alimentary 2551 
Pharmacology & Therapeutics. 2011; 33: 895-901. 2552 
170. Bijkerk CJ, Muris JWM, Knottnerus JA, Hoes AW and De Wit NJ. Systematic review: 2553 
the role of different types of fibre in the treatment of irritable bowel syndrome. Alimentary 2554 
Pharmacology and Therapeutics. 2004; 19: 245-51. 2555 
171. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint 2556 
oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2557 
2008; 337: a2313. 2558 
172. Ashraf W, Park F, Lof J and Quigley EMM. Effects of psyllium therapy on stool 2559 
characteristics, colon transit and anorectal function in chronic idiopathic constipation. 2560 
Alimentary Pharmacology & Therapeutics. 2007; 9: 639-47. 2561 
173. Badiali D, Corazziari E, Habib FI, et al. Effect of wheat bran in treatment of chronic 2562 
nonorganic constipation: A double-blind controlled trial. Digestive Diseases and Sciences. 2563 
1995; 40: 349-56. 2564 
174. Hongisto SM, Paajanen L, Saxelin M and Korpela R. A combination of fibre-rich rye 2565 
bread and yoghurt containing Lactobacillus GG improves bowel function in women with self-2566 
reported constipation. European Journal of Clinical Nutrition. 2006; 60: 319-24. 2567 
175. Bijkerk CJ, de Wit NJ, Muris JWM, Whorwell PJ, Knottnerus JA and Hoes AW. Soluble 2568 
or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo 2569 
controlled trial. BMJ. 2009; 339: b3154-b. 2570 
176. Odes HS and Madar Z. A double-blind trial of a celandin, aloevera and psyllium 2571 
laxative preparation in adult patients with constipation. Digestion. 1991; 49: 65-71. 2572 
177. López Román J, Martínez Gonzálvez AB, Luque A, et al. Efecto de la ingesta de un 2573 
preparado lácteo con fibra dietética sobre el estreñimiento crónico primario idiopático. 2574 
Nutrición Hospitalaria. 2008; 23: 12-9. 2575 
178. Fenn GC, Wilkinson PD, Lee CE and Akbar FA. A general practice study of the efficacy 2576 
of Regulan in functional constipation. Br J Clin Pract. 1986; 40: 192-7. 2577 
179. Major G, Murray K, Singh G, et al. Demonstration of differences in colonic volumes, 2578 
transit, chyme consistency, and response to psyllium between healthy and constipated 2579 
subjects using magnetic resonance imaging. Neurogastroenterology & Motility. 2018; 30: 2580 
e13400. 2581 
180. Francis C. Bran and irritable bowel syndrome: time for reappraisal. The Lancet. 1994; 2582 
344: 39-40. 2583 
93 
 
181. Ford AC and Suares NC. Effect of laxatives and pharmacological therapies in chronic 2584 
idiopathic constipation: systematic review and meta-analysis. Gut. 2011; 60: 209-18. 2585 
182. Chapman RW, Stanghellini V, Geraint M and Halphen M. Randomized Clinical Trial: 2586 
Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation 2587 
Associated With Irritable Bowel Syndrome. The American Journal of Gastroenterology. 2013; 2588 
108: 1508-15. 2589 
183. DiPalma JA, DeRidder PH, Orlando RC, Kolts BE and Cleveland Mv. A randomized, 2590 
placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol 2591 
laxative. The American Journal of Gastroenterology. 2000; 95: 446-50. 2592 
184. DiPalma JA, Cleveland Mv, McGowan J and Herrera JL. A Randomized, Multicenter, 2593 
Placebo-Controlled Trial of Polyethylene Glycol Laxative for Chronic Treatment of Chronic 2594 
Constipation. The American Journal of Gastroenterology. 2007; 102: 1436-41. 2595 
185. Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol 2596 
electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. 2597 
Digestive Diseases and Sciences. 1996; 41: 1636-42. 2598 
186. Corazziari E. Long term efficacy, safety, and tolerabilitity of low daily doses of 2599 
isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of 2600 
functional chronic constipation. Gut. 2000; 46: 522-6. 2601 
187. Lee-Robichaud H, Thomas K, Morgan J and Nelson RL. Lactulose versus Polyethylene 2602 
Glycol for Chronic Constipation. Cochrane Database of Systematic Reviews. 2010. 2603 
188. Belsey JD, Geraint M and Dixon TA. Systematic review and meta analysis: 2604 
polyethylene glycol in adults with non-organic constipation: Polyethylene glycol in adults 2605 
with non-organic constipation. International Journal of Clinical Practice. 2010; 64: 944-55. 2606 
189. Baldonedo YC, Lugo E, Uzcategui AA, Guelrud M and Skornicki J. [Evaluation and use 2607 
of polyethylene glycol in constipated patients]. G E N. 1991; 45: 294-7. 2608 
190. Wesselius-De Casparis A, Braadbaart S, Bergh-Bohlken GE and Mimica M. Treatment 2609 
of chronic constipation with lactulose syrup: results of a double-blind study. Gut. 1968; 9: 2610 
84-6. 2611 
191. Sanders JF. Lactulose Syrup Assessed in a Double-Blind Study of Elderly Constipated 2612 
Patients. Journal of the American Geriatrics Society. 1978; 26: 236-9. 2613 
192. Attaluri A, Donahoe R, Valestin J, Brown K and Rao SSC. Randomised clinical trial: 2614 
dried plums (prunes) vs. psyllium for constipation: Randomised clinical trial: dried plums in 2615 
constipation. Alimentary Pharmacology & Therapeutics. 2011; 33: 822-8. 2616 
193. Muller-Lissner SA, Kamm MA, Scarpignato C and Wald A. Myths and misconceptions 2617 
about chronic constipation. Am J Gastroenterol. 2005; 100: 232-42. 2618 
194. Manabe N, Cremonini F, Camilleri M, Sandborn WJ and Burton DD. Effects of 2619 
bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. 2620 
Aliment Pharmacol Ther. 2009; 30: 930-6. 2621 
195. Ramkumar D and Rao SS. Efficacy and safety of traditional medical therapies for 2622 
chronic constipation: systematic review. Am J Gastroenterol. 2005; 100: 936-71. 2623 
196. An evidence-based approach to the management of chronic constipation in North 2624 
America. Am J Gastroenterol. 2005; 100 Suppl 1: S1-4. 2625 
197. Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC and Kamm MA. Efficacy and 2626 
safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, 2627 
placebo-controlled study. Aliment Pharmacol Ther. 2006; 23: 1479-88. 2628 
198. Soufi-Afshar I, Moghadamnia A, Bijani A, Kazemi S and Shokri-Shirvani J. Comparison 2629 
of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation. Caspian 2630 
J Intern Med. 2016; 7: 19-24. 2631 
199. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, 2632 
randomized, placebo-controlled trial of sodium picosulfate in patients with chronic 2633 
constipation. Am J Gastroenterol. 2010; 105: 897-903. 2634 
94 
 
200. Kienzle-Horn S, Vix JM, Schuijt C, Peil H, Jordan CC and Kamm MA. Comparison of 2635 
bisacodyl and sodium picosulphate in the treatment of chronic constipation. Curr Med Res 2636 
Opin. 2007; 23: 691-9. 2637 
201. Lemli J. Metabolism of sennosides--an overview. Pharmacology. 1988; 36 Suppl 1: 2638 
126-8. 2639 
202. Marlett JA, Li BU, Patrow CJ and Bass P. Comparative laxation of psyllium with and 2640 
without senna in an ambulatory constipated population. Am J Gastroenterol. 1987; 82: 333-2641 
7. 2642 
203. Kinnunen O and Salokannel J. The carry-over effect on the bowel habit in elderly 2643 
long-term patients of long-term bulk-forming products containing stimulant laxative. Acta 2644 
Med Scand. 1987; 222: 477-9. 2645 
204. Passmore AP, Wilson-Davies K, Stoker C and Scott ME. Chronic constipation in long 2646 
stay elderly patients: a comparison of lactulose and a senna-fibre combination. BMJ. 1993; 2647 
307: 769-71. 2648 
205. Kinnunen O, Winblad I, Koistinen P and Salokannel J. Safety and efficacy of a bulk 2649 
laxative containing senna versus lactulose in the treatment of chronic constipation in 2650 
geriatric patients. Pharmacology. 1993; 47 Suppl 1: 253-5. 2651 
206. MacLennan WJ and Pooler A. A comparison of sodium picosulphate ("Laxoberal") 2652 
with standardised senna ("Senokot") in geriatric patients. Curr Med Res Opin. 1974; 2: 641-7. 2653 
207. Marciniak CM, Toledo S, Lee J, et al. Lubiprostone vs Senna in postoperative 2654 
orthopedic surgery patients with opioid-induced constipation: a double-blind, active-2655 
comparator trial. World J Gastroenterol. 2014; 20: 16323-33. 2656 
208. Muller-Lissner S. Pharmacokinetic and pharmacodynamic considerations for the 2657 
current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013; 9: 391-401. 2658 
209. Willems M, van Buuren HR and de Krijger R. Anthranoid self-medication causing 2659 
rapid development of melanosis coli. Neth J Med. 2003; 61: 22-4. 2660 
210. Brenner DM. Stimulant laxatives for the treatment of chronic constipation: is it time 2661 
to change the paradigm? Gastroenterology. 2012; 142: 402-4. 2662 
211. Shin A, Camilleri M, Kolar G, Erwin P, West CP and Murad MH. Systematic review 2663 
with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) 2664 
in chronic constipation. Alimentary Pharmacology & Therapeutics. 2014; 39: 239-53. 2665 
212. Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and Safety of Prucalopride in 2666 
Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. 2667 
Digestive Diseases and Sciences. 2016; 61: 2357-72. 2668 
213. Tack J, Quigley E, Camilleri M, Vandeplassche L and Kerstens R. Efficacy and safety of 2669 
oral prucalopride in women with chronic constipation in whom laxatives have failed: an 2670 
integrated analysis. United European Gastroenterology Journal. 2013; 1: 48-59. 2671 
214. Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P and Vandeplassche 2672 
L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic 2673 
constipation - follow-up of patients from the pivotal studies: Clinical trial: long-term 2674 
prucalopride in chronic constipation. Alimentary Pharmacology & Therapeutics. 2010; 32: 2675 
1113-23. 2676 
215. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S and Zinsmeister AR. 2677 
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation 2678 
without a rectal evacuation disorder. Gastroenterology. 2001; 120: 354-60. 2679 
216. Sajid MS, Hebbar M, Baig MK, Li A and Philipose Z. Use of Prucalopride for Chronic 2680 
Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled 2681 
Trials. Journal of neurogastroenterology and motility. 2016; 22: 412-22. 2682 
217. Ponec RJ, Saunders MD and Kimmey MB. Neostigmine for the treatment of acute 2683 
colonic pseudo-obstruction. N Engl J Med. 1999; 341: 137-41. 2684 
95 
 
218. Korsten MA, Rosman AS, Ng A, et al. Infusion of neostigmine-glycopyrrolate for 2685 
bowel evacuation in persons with spinal cord injury. Am J Gastroenterol. 2005; 100: 1560-5. 2686 
219. Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal 2687 
motility in patients with suspected gastrointestinal motility disorders. 2688 
Neurogastroenterology and motility : the official journal of the European Gastrointestinal 2689 
Motility Society. 2015; 27: 1736-46. 2690 
220. Nowlan ML and Scott LJ. Acotiamide: first global approval. Drugs. 2013; 73: 1377-83. 2691 
221. McNicol ED, Boyce D, Schumann R and Carr DB. Mu-opioid antagonists for opioid-2692 
induced bowel dysfunction. Cochrane Database of Systematic Reviews. 2008. 2693 
222. McNicol E, Boyce DB, Schumann R and Carr D. Efficacy and safety of mu-opioid 2694 
antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and 2695 
meta-analysis of randomized controlled trials. Pain Med. 2008; 9: 634-59. 2696 
223. Ford AC, Brenner DM and Schoenfeld PS. Efficacy of Pharmacological Therapies for 2697 
the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis. The 2698 
American Journal of Gastroenterology. 2013; 108: 1566-74. 2699 
224. Jansen J-P, Lorch D, Langan J, et al. A Randomized, Placebo-Controlled Phase 3 Trial 2700 
(Study SB-767905/012) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients With 2701 
Non-Cancer Pain. The Journal of Pain. 2011; 12: 185-93. 2702 
225. Irving G, Pénzes J, Ramjattan B, et al. A Randomized, Placebo-Controlled Phase 3 2703 
Trial (Study SB-767905/013) of Alvimopan for Opioid-Induced Bowel Dysfunction in Patients 2704 
With Non-Cancer Pain. The Journal of Pain. 2011; 12: 175-84. 2705 
226. Mehta N, O’Connell K, Giambrone GP, Baqai A and Diwan S. Efficacy of 2706 
methylnaltrexone for the treatment of opiod-induced constipation: a meta-analysis and 2707 
systematic review. Postgraduate Medicine. 2016; 128: 282-9. 2708 
227. Kolbow J, Modess C, Wegner D, et al. Extended-release but not immediate-release 2709 
and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-2710 
gut transit time in healthy subjects. The Journal of Clinical Pharmacology. 2016; 56: 239-45. 2711 
228. Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C and Forbes WP. Fixed-Dose 2712 
Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced 2713 
Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. 2714 
Journal of Palliative Medicine. 2015; 18: 593-600. 2715 
229. Nalamachu SR, Pergolizzi J, Taylor R, et al. Efficacy and Tolerability of Subcutaneous 2716 
Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A 2717 
Responder Analysis of 2 Randomized, Placebo-Controlled Trials. Pain Practice. 2015; 15: 564-2718 
71. 2719 
230. Webster LR, Yamada T and Arjona Ferreira JC. A Phase 2b, Randomized, Double-2720 
Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the 2721 
Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain 2722 
Medicine. 2017; 18: 2350-60. 2723 
231. Lawson R, Ryan J, King F, Goh JW, Tichy E and Marsh K. Cost Effectiveness of 2724 
Naloxegol for Opioid-Induced Constipation in the UK. PharmacoEconomics. 2017; 35: 225-2725 
35. 2726 
232. Tack J, Lappalainen J, Diva U, Tummala R and Sostek M. Efficacy and safety of 2727 
naloxegol in patients with opioid-induced constipation and laxative-inadequate response. 2728 
United European Gastroenterology Journal. 2015; 3: 471-80. 2729 
233. Yuan C-S, Foss JF, Osinski J, Toledano A, Roizen MF and Moss J. The safety and 2730 
efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit 2731 
time*. Clinical Pharmacology & Therapeutics. 1997; 61: 467-75. 2732 
234. Yuan C-S, Foss JF, O'Connor M, Toledano A, Roizen MF and Moss J. 2733 
Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without 2734 
96 
 
affecting analgesia: A double-blind randomized placebo-controlled trial*. Clinical 2735 
Pharmacology & Therapeutics. 1996; 59: 469-75. 2736 
235. Webster L, Chey WD, Tack J, Lappalainen J, Diva U and Sostek M. Randomised 2737 
clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and 2738 
opioid-induced constipation. Alimentary Pharmacology & Therapeutics. 2014; 40: 771-9. 2739 
236. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN and Tack J. Naloxegol for 2740 
Opioid-Induced Constipation in Patients with Noncancer Pain. New England Journal of 2741 
Medicine. 2014; 370: 2387-96. 2742 
237. Gonenne J, Camilleri M, Ferber I, et al. Effect of Alvimopan and Codeine on 2743 
Gastrointestinal Transit: A Randomized Controlled Study. Clinical Gastroenterology and 2744 
Hepatology. 2005; 3: 784-91. 2745 
238. Nelson AD, Camilleri M, Chirapongsathorn S, et al. Comparison of efficacy of 2746 
pharmacological treatments for chronic idiopathic constipation: a systematic review and 2747 
network meta-analysis. Gut. 2017; 66: 1611-22. 2748 
239. Atluri DK, Chandar AK, Bharucha AE and Falck-Ytter Y. Effect of linaclotide in irritable 2749 
bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. 2750 
Neurogastroenterology & Motility. 2014; 26: 499-509. 2751 
240. Videlock EJ, Cheng V and Cremonini F. Effects of Linaclotide in Patients With Irritable 2752 
Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis. Clinical 2753 
Gastroenterology and Hepatology. 2013; 11: 1084-92.e3. 2754 
241. Johanson JF, Morton D, Geenen J and Ueno R. Multicenter, 4-Week, Double-Blind, 2755 
Randomized, Placebo-Controlled Trial of Lubiprostone, a Locally-Acting Type-2 Chloride 2756 
Channel Activator, in Patients With Chronic Constipation. The American Journal of 2757 
Gastroenterology. 2008; 103: 170-7. 2758 
242. Johanson JF and Ueno R. Lubiprostone, a locally acting chloride channel activator, in 2759 
adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging 2760 
study to evaluate efficacy and safety: LUBIPROSTONE FOR CHRONIC CONSTIPATION. 2761 
Alimentary Pharmacology & Therapeutics. 2007; 25: 1351-61. 2762 
243. Johanson JF, Drossman DA, Panas R, Wahle A and Ueno R. Clinical trial: phase 2 2763 
study of lubiprostone for irritable bowel syndrome with constipation: CLINICAL TRIAL: 2764 
LUBIPROSTONE FOR IBS WITH CONSTIPATION. Alimentary Pharmacology & Therapeutics. 2765 
2008; 27: 685-96. 2766 
244. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel 2767 
activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in 2768 
healthy volunteers. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2769 
2006; 290: G942-G7. 2770 
245. Pennington B, Marriott ER, Lichtlen P, Akbar A and Hatswell AJ. The Cost 2771 
Effectiveness of Lubiprostone in Chronic Idiopathic Constipation. Pharmacoecon Open. 2018; 2772 
2: 241-53. 2773 
246. Shah E and Pimentel M. Evaluating the functional net value of pharmacologic agents 2774 
in treating irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2014; 39: 2775 
973-83. 2776 
247. Chiarioni G and Whitehead WE. The role of biofeedback in the treatment of 2777 
gastrointestinal disorders. Nature Clinical Practice Gastroenterology & Hepatology. 2008; 5: 2778 
371-82. 2779 
248. Chiarioni G, Whitehead WE, Pezza V, Morelli A and Bassotti G. Biofeedback Is 2780 
Superior to Laxatives for Normal Transit Constipation Due to Pelvic Floor Dyssynergia. 2781 
Gastroenterology. 2006; 130: 657-64. 2782 
249. Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D and Whitehead WE. 2783 
Randomized, Controlled Trial Shows Biofeedback to be Superior to Alternative Treatments 2784 
97 
 
for Patients with Pelvic Floor Dyssynergia-Type Constipation. Diseases of the Colon & 2785 
Rectum. 2007; 50: 428-41. 2786 
250. Rao SSC, Seaton K, Miller M, et al. Randomized Controlled Trial of Biofeedback, 2787 
Sham Feedback, and Standard Therapy for Dyssynergic Defecation. Clinical Gastroenterology 2788 
and Hepatology. 2007; 5: 331-8. 2789 
251. Rao SSC, Valestin J, Brown CK, Zimmerman B and Schulze K. Long-Term Efficacy of 2790 
Biofeedback Therapy for Dyssynergic Defecation: Randomized Controlled Trial. The 2791 
American Journal of Gastroenterology. 2010; 105: 890-6. 2792 
252. Lee HJ, Boo SJ, Jung KW, et al. Long-term efficacy of biofeedback therapy in patients 2793 
with dyssynergic defecation: results of a median 44 months follow-up. 2794 
Neurogastroenterology & Motility. 2015; 27: 787-95. 2795 
253. Lehur PA, Stuto A, Fantoli M, et al. Outcomes of Stapled Transanal Rectal Resection 2796 
vs. Biofeedback for the Treatment of Outlet Obstruction Associated with Rectal 2797 
Intussusception and Rectocele: A Multicenter, Randomized, Controlled Trial. Diseases of the 2798 
Colon & Rectum. 2008; 51: 1611-8. 2799 
254. Patcharatrakul T, Valestin J, Schmeltz A, Schulze K and Rao SSC. Factors Associated 2800 
With Response to Biofeedback Therapy for Dyssynergic Defecation. Clinical 2801 
Gastroenterology and Hepatology. 2018; 16: 715-21. 2802 
255. Chiarioni G. Biofeedback treatment of chronic constipation: myths and 2803 
misconceptions. Techniques in Coloproctology. 2016; 20: 611-8. 2804 
256. Etherson KJ, Horrocks EJ, Scott SM, Knowles CH and Yiannakou Y. A National 2805 
Biofeedback Practitioners Service Evaluation: Focus on Chronic Idiopathic Constipation. 2806 
Frontline Gastroenterology. 2017; 8: 62-7. 2807 
257. Iqbal F, Askari A, Adaba F, et al. Factors Associated With Efficacy of Nurse-led Bowel 2808 
Training of Patients With Chronic Constipation. Clinical Gastroenterology and Hepatology. 2809 
2015; 13: 1785-92. 2810 
258. Bellini M, Usai-Satta P, Bove A, et al. Chronic constipation diagnosis and treatment 2811 
evaluation: the “CHRO.CO.DI.T.E.” study. BMC Gastroenterology. 2017; 17. 2812 
259. Koutsomanis D, Lennard-Jones JE, Roy AJ and Kamm MA. Controlled randomised 2813 
trial of visual biofeedback versus muscle training without a visual display for intractable 2814 
constipation. Gut. 1995; 37: 95-9. 2815 
260. Norton C, Emmanuel A, Stevens N, et al. Habit training versus habit training with 2816 
direct visual biofeedback in adults with chronic constipation: study protocol for a 2817 
randomised controlled trial. Trials. 2017; 18. 2818 
261. Wang X and Yin J. Complementary and Alternative Therapies for Chronic 2819 
Constipation. Evidence-Based Complementary and Alternative Medicine. 2015; 2015: 1-11. 2820 
262. Peng W, Liang H, Sibbritt D and Adams J. Complementary and alternative medicine 2821 
use for constipation: a critical review focusing upon prevalence, type, cost, and users’ 2822 
profile, perception and motivations. International Journal of Clinical Practice. 2016; 70: 712-2823 
22. 2824 
263. Rahimi R. Herbal medicines for the management of irritable bowel syndrome: A 2825 
comprehensive review. World Journal of Gastroenterology. 2012; 18: 589. 2826 
264. Grundmann O. Complementary and alternative medicines in irritable bowel 2827 
syndrome: An integrative view. World Journal of Gastroenterology. 2014; 20: 346. 2828 
265. Shen Y-HA and Nahas R. Complementary and alternative medicine for treatment of 2829 
irritable bowel syndrome. Can Fam Physician. 2009; 55: 143-8. 2830 
266. Bensoussan A, Kellow JE, Bourchier SJ, et al. Efficacy of a Chinese Herbal Medicine in 2831 
Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A 2832 
Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015; 13: 1946-54 e1. 2833 
98 
 
267. Zhang C, Guo L, Guo X, Li G and Guo X. Short and long-term efficacy of combining 2834 
Fuzhengliqi mixture with acupuncture in treatment of functional constipation. Journal of 2835 
Traditional Chinese Medicine. 2013; 33: 51-9. 2836 
268. Huang C-H, Su Y-C, Li T-C, et al. Treatment of Constipation in Long-Term Care with 2837 
Chinese Herbal Formula: A Randomized, Double-Blind Placebo-Controlled Trial. The Journal 2838 
of Alternative and Complementary Medicine. 2011; 17: 639-46. 2839 
269. Jia G, Meng M-B, Huang Z-W, et al. Treatment of functional constipation with the 2840 
Yun-chang capsule: A double-blind, randomized, placebo-controlled, dose-escalation trial: 2841 
YCC for treating FC. Journal of Gastroenterology and Hepatology. 2010; 25: 487-93. 2842 
270. Cheng C-W, Bian Z-X, Zhu L-X, Wu JCY and Sung JJY. Efficacy of a Chinese Herbal 2843 
Proprietary Medicine (Hemp Seed Pill) for Functional Constipation. The American Journal of 2844 
Gastroenterology. 2011; 106: 120-9. 2845 
271. Bian ZX, Cheng CW and Zhu LZ. Chinese herbal medicine for functional constipation: 2846 
a randomised controlled trial. Hong Kong Med J. 2013; 19 Suppl 9: 44-6. 2847 
272. Manheimer E, Wieland LS, Cheng K, et al. Acupuncture for Irritable Bowel Syndrome: 2848 
Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 2012; 107: 2849 
835-47. 2850 
273. Xue Q-m, Li N, Liu Z-s, Wang C-w and Lu J-q. Efficacy of electroacupuncture in the 2851 
treatment of functional constipation: A randomized controlled pilot trial. Chinese Journal of 2852 
Integrative Medicine. 2015; 21: 459-63. 2853 
274. Zhang T, Chon TY, Liu B, et al. Efficacy of Acupuncture for Chronic Constipation: A 2854 
Systematic Review. The American Journal of Chinese Medicine. 2013; 41: 717-42. 2855 
275. Lee MS, Choi T-Y, Park J-E and Ernst E. Effects of moxibustion for constipation 2856 
treatment: a systematic review of randomized controlled trials. Chinese Medicine. 2010; 5: 2857 
28. 2858 
276. Park J-E, Sul J-U, Kang K, Shin B-C, Hong K-E and Choi S-M. The effectiveness of 2859 
moxibustion for the treatment of functional constipation: a randomized, sham-controlled, 2860 
patient blinded, pilot clinical trial. BMC Complementary and Alternative Medicine. 2011; 11. 2861 
277. Ottillinger B, Storr M, Malfertheiner P and Allescher H-D. STW 5 (Iberogast®)—a safe 2862 
and effective standard in the treatment of functional gastrointestinal disorders. Wiener 2863 
Medizinische Wochenschrift. 2013; 163: 65-72. 2864 
278. Cirillo C and Capasso R. Constipation and Botanical Medicines: An Overview: 2865 
Constipation and Botanical Medicines. Phytotherapy Research. 2015; 29: 1488-93. 2866 
279. Elsagh M, Fartookzadeh MR, Kamalinejad M, et al. Efficacy of the Malva sylvestris L. 2867 
flowers aqueous extract for functional constipation: A placebo-controlled trial. 2868 
Complementary Therapies in Clinical Practice. 2015; 21: 105-11. 2869 
280. Iturrino J, Camilleri M, Wong BS, Linker Nord SJ, Burton D and Zinsmeister AR. 2870 
Randomised clinical trial: the effects of daikenchuto, TU-100, on gastrointestinal and colonic 2871 
transit, anorectal and bowel function in female patients with functional constipation. 2872 
Alimentary Pharmacology & Therapeutics. 2013; 37: 776-85. 2873 
281. van Tilburg MAL, Palsson OS, Ringel Y and Whitehead WE. Is ginger effective for the 2874 
treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. 2875 
Complementary Therapies in Medicine. 2014; 22: 17-20. 2876 
282. Brinkhaus B, Hentschel C, Keudell CV, et al. Herbal medicine with curcuma and 2877 
fumitory in the treatment of irritable bowel syndrome: A randomized, placebo-controlled, 2878 
double-blind clinical trial. Scand J Gastroentero. 2005; 40: 936-43. 2879 
283. Lämås K, Lindholm L, Engström B and Jacobsson C. Abdominal massage for people 2880 
with constipation: a cost utility analysis: Abdominal massage for people with constipation. 2881 
Journal of Advanced Nursing. 2010; 66: 1719-29. 2882 
99 
 
284. Lämås K, Lindholm L, Stenlund H, Engström B and Jacobsson C. Effects of abdominal 2883 
massage in management of constipation—A randomized controlled trial. International 2884 
Journal of Nursing Studies. 2009; 46: 759-67. 2885 
285. Silva CAG and Motta MEFA. The use of abdominal muscle training, breathing 2886 
exercises and abdominal massage to treat paediatric chronic functional constipation. 2887 
Colorectal Disease. 2013; 15: e250-e5. 2888 
286. Sinclair M. The use of abdominal massage to treat chronic constipation. Journal of 2889 
Bodywork and Movement Therapies. 2011; 15: 436-45. 2890 
287. Ford AC, Quigley EMM, Lacy BE, et al. Effect of Antidepressants and Psychological 2891 
Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and 2892 
Meta-Analysis. The American Journal of Gastroenterology. 2014; 109: 1350-65. 2893 
288. Paré P, Bridges R, Champion MC, et al. Recommendations on chronic constipation 2894 
(including constipation associated with irritable bowel syndrome) treatment. Can J 2895 
Gastroenterol. 2007; 21 Suppl B: 3B-22B. 2896 
289. Mendoza J, Legido J, Rubio S and Gisbert JP. Systematic review: the adverse effects 2897 
of sodium phosphate enema: SYSTEMATIC REVIEW: ADVERSE EFFECTS OF SODIUM 2898 
PHOSPHATE ENEMA. Alimentary Pharmacology & Therapeutics. 2007; 26: 9-20. 2899 
290. Emmett CD, Close HJ, Yiannakou Y and Mason JM. Trans-anal irrigation therapy to 2900 
treat adult chronic functional constipation: systematic review and meta-analysis. BMC 2901 
Gastroenterology. 2015; 15. 2902 
291. Christensen P, Krogh K, Perrouin-Verbe B, et al. Global audit on bowel perforations 2903 
related to transanal irrigation. Techniques in Coloproctology. 2016; 20: 109-15. 2904 
292. Members of the working group on Trans Anal Irrigation from Uk DIGF, the N, 2905 
Emmanuel AV, et al. Consensus review of best practice of transanal irrigation in adults. 2906 
Spinal Cord. 2013; 51: 732-8. 2907 
293. Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus 2908 
placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, 2909 
placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018; 3: 2910 
17-24. 2911 
294. Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters 2912 
gut microbiota in patients with irritable bowel syndrome: results from a randomised, 2913 
double-blind placebo-controlled study. Gut. 2018. 2914 
295. Ding C, Fan W, Gu L, et al. Outcomes and prognostic factors of fecal microbiota 2915 
transplantation in patients with slow transit constipation: results from a prospective study 2916 
with long-term follow-up. Gastroenterology Report. 2018; 6: 101-7. 2917 
296. Tian H, Ge X, Nie Y, et al. Fecal microbiota transplantation in patients with slow-2918 
transit constipation: A randomized, clinical trial. PLOS ONE. 2017; 12: e0171308. 2919 
297. Zhang X, Tian H, Gu L, et al. Long-term follow-up of the effects of fecal microbiota 2920 
transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow 2921 
transit constipation. Science China Life Sciences. 2018; 61: 779-86. 2922 
298. Moreira TR, Leonhardt D and Conde SR. Influence of Drinking a Probiotic Fermented 2923 
Milk Beverage Containing Bifidobacterium Animalis on the Symptoms of Constipation. Arq 2924 
Gastroenterol. 2017; 54: 206-10. 2925 
299. Spiller R, Pelerin F, Cayzeele Decherf A, et al. Randomized double blind placebo-2926 
controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: 2927 
improvement in abdominal pain and bloating in those with predominant constipation. 2928 
United European Gastroenterol J. 2016; 4: 353-62. 2929 
300. Mezzasalma V, Manfrini E, Ferri E, et al. A Randomized, Double-Blind, Placebo-2930 
Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating 2931 
Symptoms of Irritable Bowel Syndrome Associated with Constipation. Biomed Res Int. 2016; 2932 
2016: 4740907. 2933 
100 
 
301. Kim SE, Choi SC, Park KS, et al. Change of Fecal Flora and Effectiveness of the Short-2934 
term VSL#3 Probiotic Treatment in Patients With Functional Constipation. Journal of 2935 
neurogastroenterology and motility. 2015; 21: 111-20. 2936 
302. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics 2937 
in irritable bowel syndrome and chronic idiopathic constipation: systematic review and 2938 
meta-analysis. Am J Gastroenterol. 2014; 109: 1547-61; quiz 6, 62. 2939 
303. Mazlyn MM, Nagarajah LH, Fatimah A, Norimah AK and Goh KL. Effects of a probiotic 2940 
fermented milk on functional constipation: a randomized, double-blind, placebo-controlled 2941 
study. J Gastroenterol Hepatol. 2013; 28: 1141-7. 2942 
304. Choi SC, Kim BJ, Rhee PL, et al. Probiotic Fermented Milk Containing Dietary Fiber 2943 
Has Additive Effects in IBS with Constipation Compared to Plain Probiotic Fermented Milk. 2944 
Gut Liver. 2011; 5: 22-8. 2945 
305. Knowles CH, Grossi U, Horrocks EJ, et al. Surgery for constipation: systematic review 2946 
and practice recommendations: Graded practice and future research recommendations. 2947 
Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain 2948 
and Ireland. 2017; 19 Suppl 3: 101-13. 2949 
306. Arebi N, Kalli T, Howson W, Clark S and Norton C. Systematic review of abdominal 2950 
surgery for chronic idiopathic constipation: Surgical outcomes in constipation. Colorectal 2951 
Disease. 2011; 13: 1335-43. 2952 
307. Pfeifer J. Surgical options to treat constipation: A brief overview. Rozhl Chir. 2015; 2953 
94: 349-61. 2954 
308. Bove A. Consensus statement AIGO/SICCR diagnosis and treatment of chronic 2955 
constipation and obstructed defecation (Part II: Treatment). World Journal of 2956 
Gastroenterology. 2012; 18: 4994. 2957 
309. Duchalais E, Meurette G, Mantoo SK, et al. Percutaneous endoscopic caecostomy for 2958 
severe constipation in adults: feasibility, durability, functional and quality of life results at 1 2959 
year follow-up. Surgical Endoscopy. 2015; 29: 620-6. 2960 
310. Meurette G, Lehur PA, Coron E and Regenet N. Long-term results of Malone's 2961 
procedure with antegrade irrigation for severe chronic constipation. Gastroentérologie 2962 
Clinique et Biologique. 2010; 34: 209-12. 2963 
311. Sturkenboom R, van der Wilt AA, van Kuijk SMJ, et al. Long-term outcomes of a 2964 
Malone antegrade continence enema (MACE) for the treatment of fecal incontinence or 2965 
constipation in adults. International journal of colorectal disease. 2018. 2966 
312. Dinning PG, Hunt L, Patton V, et al. Treatment Efficacy of Sacral Nerve Stimulation in 2967 
Slow Transit Constipation: A Two-Phase, Double-Blind Randomized Controlled Crossover 2968 
Study. The American Journal of Gastroenterology. 2015; 110: 733-40. 2969 
313. Patton V, Stewart P, Lubowski DZ, Cook IJ and Dinning PG. Sacral Nerve Stimulation 2970 
Fails to Offer Long-term Benefit in Patients With Slow-Transit Constipation. Diseases of the 2971 
Colon & Rectum. 2016; 59: 878-85. 2972 
314. Pilkington SA, Emmett C, Knowles CH, et al. Surgery for constipation: systematic 2973 
review and practice recommendations: Results V: Sacral Nerve Stimulation. Colorectal 2974 
Disease. 2017; 19: 92-100. 2975 
315. Zerbib F, Siproudhis L, Lehur PA, et al. Randomized clinical trial of sacral nerve 2976 
stimulation for refractory constipation. British Journal of Surgery. 2017; 104: 205-13. 2977 
316. Knowles CH, Grossi U, Chapman M, Mason J, the NCwg and Pelvic floor S. Surgery 2978 
for constipation: systematic review and practice recommendations: Results I: Colonic 2979 
resection. Colorectal Disease. 2017; 19: 17-36. 2980 
317. Grossi U, Horrocks EJ, Mason J, et al. Surgery for constipation: systematic review and 2981 
practice recommendations: Results IV: Recto-vaginal reinforcement procedures. Colorectal 2982 
Disease. 2017; 19: 73-91. 2983 
101 
 
318. Grossi U, Knowles CH, Mason J, et al. Surgery for constipation: systematic review 2984 
and practice recommendations: Results II: Hitching procedures for the rectum (rectal 2985 
suspension). Colorectal Disease. 2017; 19: 37-48. 2986 
319. Mercer-Jones M, Grossi U, Pares D, et al. Surgery for constipation: systematic review 2987 
and practice recommendations: Results III: Rectal wall excisional procedures (Rectal 2988 
Excision). Colorectal Disease. 2017; 19: 49-72. 2989 
320. Wald A. Constipation: Advances in Diagnosis and Treatment. JAMA. 2016; 315: 185. 2990 
321. Rao SSC, Bharucha AE, Chiarioni G, et al. Anorectal Disorders. Gastroenterology. 2991 
2016; 150: 1430-42.e4. 2992 
322. Chiarioni G, Kim SM, Vantini I and Whitehead WE. Validation of the Balloon 2993 
Evacuation Test: Reproducibility and Agreement With Findings From Anorectal Manometry 2994 
and Electromyography. Clinical Gastroenterology and Hepatology. 2014; 12: 2049-54. 2995 
323. Chiarioni G. Biofeedback therapy for dyssynergic defecation. World Journal of 2996 
Gastroenterology. 2006; 12: 7069. 2997 
324. Burnett CA. Nurse management of intractable functional constipation: a randomised 2998 
controlled trial. Archives of Disease in Childhood. 2004; 89: 717-22. 2999 
325. Mearin F, Ciriza C, Mínguez M, et al. Guía de práctica clínica del síndrome del 3000 
intestino irritable con estreñimiento y estreñimiento funcional en adultos: tratamiento. 3001 
(Parte 2 de 2). SEMERGEN - Medicina de Familia. 2017; 43: 123-40. 3002 
326. Serra J, Mascort-Roca J, Marzo-Castillejo M, et al. Guía de práctica clínica sobre el 3003 
manejo del estreñimiento crónico en el paciente adulto. Parte 2: Diagnóstico y tratamiento. 3004 
Gastroenterología y Hepatología. 2017; 40: 303-16. 3005 
 3006 
  3007 
102 
 
TABLE 1. Level of evidence and strength of recommendation of the different 3008 
statements related to diagnostic approaches and treatment groups (%). 3009 
 3010 
    Level of evidence  Recommendation 3011 
 
High Moderate Low Very low 
 
Strong Weak 
        Clinical approach 0 67 16,5 16,5 
 
67 33 
Functional studies 14 43 29 14 
 
100 0 
Radiological studies 0 30 60 10 
 
67 33 
        General measures 0 50 50 0 
 
75 25 
Bulking/osmotics 25 50 25 0 
 
75 25 
Stimulant 0 83 17 0 
 
67 33 
Prokinetics/secretagoges 67 16.5 16.5 0 
 
67 33 
Biofeedback 0 50 50 0 
 
50 50 
Alternative treatments 0 0 44 56 
 
22 78 
Probiotics 0 0 100 0 
 
0 100 
Surgical treatment 0 50 33 17 
 
83 17 
3012 
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FIGURE LEGENDS 3013 
Figure 1. Final agreement between the authors for each of the statements 3014 
produced after the Delphi consensus process. 3015 
 3016 
Figure 2. Algorithm 1. Management of constipation. First-line management of 3017 
patients presenting with constipation at any level of the health-care 3018 
system. 3019 
1. Defined as difficult, unsatisfactory or infrequent defecation for at least 3020 
the previous 3 months. 3021 
2. Rescue therapy may include suppositories or rectal enemas, if 3022 
accepted by the patient, or the use of fibre or osmotic laxatives on 3023 
demand. Level of evidence very low. Recommendation strong.  3024 
3. Use of probiotics seems promising, however no strong evidence yet. 3025 
4. When available, anorectal function testing may be indicated at this 3026 
stage when there is clinical suspicion of an evacuation disorder 3027 
(manual manoeuvres, haemorrhoids, prolapse or rectocele, painful 3028 
evacuation, etc.) 3029 
5. Alternatively, other treatments like prokinetics or secretagogues could 3030 
be tried. 3031 
 3032 
Figure 3. Algorithm 2. Further investigation of constipation. 3033 
1. Anorectal function testing with manometry should ideally include a 3034 
balloon expulsion test. Depending on local availability and expertise, 3035 
defecography could also be performed at this stage (either barium or 3036 
magnetic resonance). 3037 
2. According to the Rome IV consensus, functional defecation disorder 3038 
(FDD) is defined as: 3039 
104 
 
I. The patient must satisfy diagnostic criteria for functional constipation and/or 3040 
irritable bowel syndrome with constipation 3041 
II. During repeated attempts to defecate, there must be features of impaired 3042 
evacuation, as demonstrated by 2 of the following 3 tests: 3043 
a. Abnormal balloon expulsion test 3044 
b. Abnormal anorectal evacuation pattern with manometry or anal surface EMG 3045 
c. Impaired rectal evacuation by imaging 3046 
 3047 
Subcategories for FDD 3048 
a). Diagnostic Criteria for Inadequate Defecatory Propulsion 3049 
Inadequate propulsive forces as measured with manometry with or without 3050 
inappropriate contraction of the anal sphincter and/or pelvic floor musclesb 3051 
b). Diagnostic Criteria for Dyssynergic Defecation 3052 
Inappropriate contraction of the pelvic floor as measured with anal surface EMG or 3053 
manometry with adequate propulsive forces during attempted defecationb 3054 
 3055 
Criteria fulfilled for the last 3 months with symptom onset at least 6 months before 3056 
diagnosis. 3057 
These criteria are defined by age- and sex-appropriate normal values for the 3058 
technique. 3059 
 3060 
3. Before considering any surgical correction, evaluate the feasibility 3061 
of biofeedback treatment as the option with the least side effects. 3062 
4. Evaluation of colonic transit time can be useful in patients without 3063 
evacuation disorders, as well as in patients with persistent 3064 
constipation after treated evacuation disorders. 3065 
5. This means according to Rome IV: Chronic constipation due to 3066 
"Disease-related", "Medication-induced" or "IBS-C“. At this stage 3067 
105 
 
further investigation or symptomatic treatment will be considered.  3068 
 3069 
Figure 4. Algorithm 3. Treatment of constipation not caused by an evacuation 3070 
disorder and refractory to first-line management. 3071 
1. The first choice will depend on the patient’s characteristics, like 3072 
coexistence of abdominal pain or distension, cost/efficacy evaluation, 3073 
and local preferences. 3074 
2. As rescue therapy, stimulant laxatives may be used, as well as 3075 
suppositories, rectal enemas or rectal irrigation. 3076 
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